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Abstract
Diabetes is a serious public health threat that leads to a variety of complications
including diabetic nephropathy. Initiated by elevated blood glucose levels,
glomerular and proximal tubule damage promotes progressive nephron deterioration
leading to end stage renal failure. A common indicator of impending kidney failure is
an increase in urinary albumin levels. Urinary proteins are efficiently reabsorbed via
receptor-mediated endocytosis in the epithelial cells of the renal proximal tubules by
endocytic proteins megalin and cubilin. CD13 has been previously identified as a
negative regulator of receptor-mediated endocytosis of numerous cell types. Urinary
albumin levels were significantly decreased in CD13KO animals compared to wild
type animals in models of diabetic nephropathy and albumin overload. CD13
negatively regulates receptor-mediated endocytosis of albumin in proximal tubules.
Currently, there are limited reliable biomarkers that accurately detect renal injury and
its progression. Single-pass, apically expressed proximal tubule brush border
proteins (CD10, CD13 and CD26) were easily shed into the urine predicting renal
obstruction in patients with ureteropelvic junction obstruction. Targeting reliable
noninvasive biomarkers of renal injury is critical to diagnosing patients at risk.
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Introduction

________________________________

1

1.1 – Kidney Disease
Chronic kidney disease
Chronic kidney disease (CKD) affects millions of Americans yearly leading to
increased medical expenditures, continuous patient monitoring, a decreased quality
of life and an increase in morbidity and mortality. Of the 26 million affected yearly in
the United States, approximately 1.8 million of these patients are treated for endstage renal disease (ESRD) by renal replacement therapy involving kidney
transplant, hemodialysis or peritoneal dialysis1. Due to the increasing prevalence of
disease, developing and developed countries face significant financial burden on
health care systems for cost of care for these patients ranging around $12 billion
annually2. Patients experience severe morbidity and mortality from this debilitating
disease that is irreversible and constantly progressive. Over time the kidney slowly
deteriorates due to etiologies from hypertension, trauma, sepsis, toxicity, congenital
abnormalities caused by obstructions within the renal tract, diabetes mellitus and
many more3,4. Characteristics of CKD include weakening of renal excretory,
homeostatic and endocrine functions1. Currently, there is minimal advancement in
limiting the progression of renal deterioration despite implementing aggressive
treatment options, which provide only some protection to the nephron.

Marcello Malpighi was the first to investigate the microanatomy of the kidney in 1666
after the introduction of a newly developed microscope. His findings determined that
that the kidneys had a filtration mechanism for the blood and was also important for
the production of urine. In 1837, Gabriel Valentin identified that patients who died
2

from proteinuria had extensive renal injury as noticed by histology5. Pioneers in the
field of renal pathology, Franz Volhard and Theodor Fahr further identified that
kidney damage often coincided with excessive protein excretion in the urine in 1914.
By 1954, Jean Oliver identified the formation of protein droplets in the cytoplasm of
tubular cells that had already excessive protein degradation1,5. Since those early
days of scientific discovery and the development of new technologies, the
pathogenesis of renal injury has been vastly studied in patients as well as various
animal models. With the introduction of renal biopsies patient’s tissue is analyzed by
light,

electron

and

immunofluorescence

microscopy

to

diagnose

various

inflammatory and non-inflammatory, acute and chronic, proteinuric and hematuric,
hypertensive and non-hypertensive and all other renal diseases5.

Pathology of CKD is irreversible and includes renal fibrosis and progressive nephron
loss especially altering structures of the glomerulus and the proximal tubules,
important components in urine filtration1,4. Cellular crescent formation around the
glomerulus and atrophy of tubules leads to proteinuria, an increase of protein in the
urine. Indicative of renal failure, proteinuria occurs once the glomerular filtration
barrier becomes overloaded requiring extensive increases in resorption capabilities
by the renal proximal tubules; a burdensome task for these epithelial cells6. In
patients, most renal dysfunction is associated with tubulointerstitial injury. Patients
with diabetes and hypertension are at high risk for albuminuria, a form of proteinuria
in which albumin levels are abnormally high in the urine7. Albumin, the most
abundant circulating plasma protein, is important as it carries metabolites, hormones,
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vitamins and drugs, acts as an acid/base buffer and aids in regulating blood
pressure and volume6,8,9. Proximal tubules mediate endocytosis of over 80% of
plasma proteins, including albumin10. Mutiligand receptors, megalin and cubilin,
found on the apical side of renal proximal tubules are important in facilitation of
receptor-mediated endocytosis of plasma proteins like albumin. Once absorbed
these proteins are subsequently delivered to the lysosomes for degradation6,8,10,11. If
endocytic uptake of albumin in the proximal tubules is impaired, excess albumin in
the lumen increases inflammation, which may lead to epithelial to mesenchymal
transition (EMT). This results in fibrosis and even more damage to the kidneys,
causing a vicious cycle of continuous stress on the renal proximal tubules9.

Diabetic nephropathy
According to the American Diabetes Association, there are over 25 million
individuals who have diabetes (type 1 and type 2) and approximately 80 million who
have prediabetes are at high risk of developing diabetes mellitus. About 20% of
patients with diabetes (type 1 or type 2) develop diabetic nephropathy approximately
10 to 20 years after the onset of the disease; making diabetes the primary cause of
ESRD with about 50% of these patients having complications from diabetes4,12-14.
This trend has only increased over the past decade, but it seems that only a minority
of diabetic individuals are exposed to certain environmental and genetic factors that
determine the fate of patients’ likelihood of developing diabetic nephropathy.
Increased glucose levels expose tubular structures to damage at the basolateral
membrane. Increased glucose filtration at the glomerulus leads to overload, resulting
4

in increased filtrate exposure at the proximal tubules14. However, the exact
pathophysiology and molecular pathways that lead to renal failure caused by
hyperglycemia remains unknown, albeit growing insight into studying disease
progression.

Diabetes threatens renal microvasculature leading to injury of various kidney cells. It
is known that patients with diabetic nephropathy experience renal hyperfiltration and
microalbuminuria followed by glomerulosclerosis and tubulointerstitial fibrosis15.
Hyperglycemia impairs the regulation of local glomerular microcirculation and
manipulates the transcription and translation of genes regulating cell growth and
survival, angiogenesis and the extracellular matrix. Uptake of glucose by the
proximal tubule triggers hyperplasia and hypertrophy leading to increases in
tubulointerstitial fibrosis, damage, hypoxia, apoptosis and renal failure.

Ureteropelvic Junction Obstruction
Ureteropelvic junction obstruction (UPJO) is a congenital anomaly that frequently
leads to renal injury and renal dysfunction in infants and children. With an estimated
incidence of 1 in 500 births, UPJO is the major cause of hydronephrosis and the
most common cause of kidney disease in children16. Blockage or complete
obstruction of one or both of the ureters prevents or impedes the flow of urine into
the bladder from the kidney. Affected children develop long-term morbidities such as
CKD and cardiovascular disease. Furthermore, obstruction underlies the majority of
children with ESRD. In its most severe form, urinary tract obstruction can lead to
5

prenatal or early infant death16-18. Other children may progress to develop CKD and
kidney failure requiring lifelong monitoring and renal replacement therapy (dialysis
and transplantation). Moreover, all of these patients with renal dysfunction are at a
greater risk of cardiovascular disease early in life17.

An early symptom of ureteral obstruction is an increase in pressure in the proximal
tubules causing distention, damage and shedding of proteins expressed on the
apical surface of the proximal tubular brush border epithelium into the urine19. While
painless, hydronephrosis can lead to progressive cellular damage due to hypoxia,
ischemia, stretching, reactive oxygen species and fibrosis. This ultimately results in
tubule cell death, tubular atrophy, interstitial inflammation and collagen deposition,
impairing growth and development of the obstructed kidney and causing
compensatory enlargement of the unaffected kidney20-22. Current therapeutic goals
focus on halting progressive renal injury and enhancing healing which is dictated by
the severity and location of the obstruction. Progress in these areas is severely
hindered by the scarcity of dependable biomarkers to assess the effects of
obstruction20,23.

1.2 – Kidney Background
Structure and function of kidney
The kidneys, an excretory organ, are located in the abdominal cavity posterior to the
wall of the abdomen on either side of the vertebral column24. As regulatory organs,
the kidneys are responsible for maintaining homeostasis of bodily fluids by
6

regulating constant volume of fluids by varying excretion of solutes and water24,25.
Furthermore, the kidneys maintain blood pressure, blood pH and electrolytes in the
blood. Remarkably, the kidneys filter about 20% of total cardiac output daily,
generating on average one liter of urine per day26.

The kidney is a highly vascularized organ consisting of two distinct regions, an outer
region referred to as the cortex and an inner region referred to as the medulla.
These two regions compose the functional unit of the kidney called the nephron; the
nephron’s main responsibility is to produce and concentrate urine. Further structures
found in the kidney include blood vessels, lymphatics and nerves. The renal artery is
the major blood supply for the organ that branches progressively ultimately leading
to the glomerular capillaries. A human kidney contains approximately 1.2 million
nephrons. Nephrons are hollowed tubes composed of a single cell layer of uniquely
specialized cells consisting of the renal corpuscle, proximal tubule, loop of Henle,
distal tubule and collecting duct. Each component of the nephron is responsible for
specific functions. The renal corpuscle contains the glomerulus and Bowman’s
capsule and is responsible for the filtration of the blood24. In this portion of the
nephron, smaller molecules are selectively sieved in the first step of urine
formation26. The next segment of the nephron, the proximal tubules, contains a
brush border responsible for the reabsorption of metabolized proteins and other
substances from the glomerular filtrate through endocytic mechanisms27. The loop of
Henle recovers water and sodium chloride from the urine. Water is then reabsorbed
in the late distal tubule and urine is then collected in the collecting ducts25.

7

Glomerulus
The initial step of urine formation begins in glomerular capillaries where plasma
filtrate passes through sieves into the Bowman’s space. The glomerular filtration
barrier is composed of capillary endothelium, glomerular basement membrane,
specialized epithelial cells and podocytes28. The tufts of capillaries comprise the
glomerulus that supplies blood via the afferent arteriole and is drained by the
efferent arteriole. Epithelial cells thin out in the Bowman’s space where these
epithelial cells are in contact with podocytes. Each podocyte is equipped with foot
processes to form the filtration barrier, which is fenestrated and allows for the
movement of small molecules across the membrane like sodium, urea and glucose.
The two major components of the slit diaphragm include nephrin and podocin to
allow for selective filtration of molecules24,29.

Proximal tubule
The proximal tubule begins at the urinary pole of the glomerulus and is composed of
three segments (S1, S2 and S3)30. Structurally, the proximal tubules are highly
polarized cells containing a brush border responsible for the filtration of water,
sodium, chloride, potassium and other solutes. The S1 segment has important
machinery that allows for efficient reabsorption, transcytosis and processing of
filtered substances found in the lumen coming from the glomerular filtrate31. Filtered
proteins are endocytosed by apical membrane receptors megalin and cubilin via
receptor-mediated clathrin-dependent endocytosis24,31,32. Internalized substances
8

are degraded by lysosomes or exit the cell across the basolateral membrane
mediated by the transport protein neonatal Fc receptor (FcRn) and returned to the
blood24. The physiological processes performed by renal proximal tubules are
important for maintaining the integrity and function of the kidney.

1.3 – Renal Processes
Albumin
Albumin (~65 kDa) is the most abundant circulating plasma protein in the
bloodstream important in regulating acid/base balances and blood pressure as well
as acting as a carrier for metabolites, hormones, vitamins, inorganic ions and
medications9,33-35. The production and excretion of albumin, a 585 amino acid,
negatively charged globular protein found in the plasma of all mammals, occurs in
the liver31. Although not essential to life, the diverseness of various functions of
albumin makes it an extremely important protein. Hypoalbuminemia, due to
malnutrition or inflammation, is associated with increased mortality. Further the total
level of albumin in the urine also correlates with the progression of renal injury and
disease9. Albumin is filtered in the glomerulus; albumin filtrate is resorbed in the
renal proximal tubules. In healthy humans the glomerulus filters up to 9 g of albumin
daily9 and only 10-15 mg is excreted into the urine34.

Increased urinary albumin levels characterize albuminuria, which typically occurs
after renal diseases progress. Albumin remains to be one of the strongest
9

biomarkers for most kidney diseases35. The definition of albuminuria in clinical
settings is when daily urinary albumin levels exceed 30 mg34. With rising levels of
albuminuria there is a decline in glomerular filtration rate (GFR) accelerating the risk
of ESRD. Further, albuminuria represents an irreversible stage of kidney disease36.
Albumin resorption is a vital process regulated by the epithelial cells of renal
proximal tubules via clathrin-dependent and receptor-mediated endocytosis after
albumin is filtered by the glomeruli37. Initial events leading to albuminuria reflects
contributions from both processes in the glomerulus and proximal tubule9,35. In
diabetic nephropathy there is an overload on the glomerulus, which leads to more
albumin filtrate leaking into the proximal tubules. Epithelial cells of the proximal
tubules are overwhelmed and experience impairment in endocytic processes of
albumin and other filtrates27. The inability to properly endocytose excess albumin
filtrates leads to the accumulation of albumin in the nephron ultimately leading to the
increases seen in the urine.

The exact effect of albuminuria on renal damage is one of the biggest controversies
in the field of renal injury. Many theories contemplate reasons for albuminuria being
such a strong indicator of renal damage. The main hypothesis in the field states that
as the disease progresses, there is an increase in proteinuria and that high
concentrations of albumin and other proteins induce inflammatory responses and
fibrosis9. In vivo studies in rats and mice have shown that albuminuria leads to
inflammation and fibrosis38,39. After an 11-day model of albumin overload (AO)
glomerular ultrastructure of the podocyte and glomerular basement membrane was
10

destroyed as visualized by electron microscopy40. Excess albumin uptake by
proximal tubules activates inflammatory and fibrogenic mediators like RANTES
(regulated on activation, normal T cell expressed and secreted), monocyte
chemotactic protein-1 (MCP-1), transforming growth factor-β (TGF-β) and nuclear
factor kappa B (NF-κB). Activation of these mediators leads to inflammation, fibrosis,
mesangial expansion and hypertension ultimately leading to progressive renal
dysfunction1,9,34,41-44.

High albumin levels leads to atrophy and apoptosis of proximal tubule cells.
Apoptosis, an active, programmed cell process occurs to avoid effects of
inflammation, whereas necrosis is a passive mechanism in which a cell accidently
dies due to environmental perturbations45. Renal tubule cell apoptosis is the
common final pathway that results in a variety of different kidney injuries46. Most
studies utilize proximal tubule cell lines to study the effects of high levels of albumin
on apoptosis and necrosis. Cells are exposed to high levels of albumin or serum
fragments and apoptosis levels have been assessed using various methods. In vitro
analysis of high albumin treatment leads to increases in apoptosis46,47. Additionally,
several in vivo models indicate that high levels of albumin induces apoptosis in both
the glomerulus and proximal tubules48-50. This evidence elucidates that albumin
leads to apoptotic damage, however it does not distinguish whether apoptosis
occurs in response to increased uptake or excess circulating fragments of albumin
present in the lumen of the nephron.

11

Renal endocytosis
A fundamental cellular process that affects every cell function is endocytosis;
classically defined as the process in which cells internalize anything from small
extracellular particles to entire cells that are incapable of passing through the plasma
membrane51-53. A key controller of cellular homeostasis, endocytosis is convoluted
as it has multiple interconnected entry routes that are regulated by cargo specificity,
receptor sorting signals, endocytic adaptors and lipids51. It is an extensively studied
process as it has shown to be involved in antigen presentation, nutrient acquisition,
elimination of apoptotic cells, pathogen entry, receptor regulation, hypertension and
synaptic transmission52. Endocytosis occurs though several distinct biochemical
mechanisms, but the best understood is through clathrin-mediated endocytosis54.
Clathrin-mediated endocytosis recruits clathrin-binding proteins to induce clathrin
polymerization to drive membrane invagination and vesicle scission51,55. Succeeding
internalization, molecules from the plasma membrane are recycled back to the
surface in recycling endosomal compartments, routed to degradation pathways
towards the lysosomes or returned into circulation by transcytosis31,51,55.

In renal proximal tubules, receptor-mediated endocytosis is crucial for resorption and
metabolism of substances found in the lumen coming from the glomerular filtrate.
Low molecular weight proteins are readily resorbed by a mechanism heavily relying
on megalin and cubilin. Healthy proximal tubules in adults take up as much as
600 mg of protein daily, however in renal injury, proximal tubules uptake machinery
becomes saturated leading to cytotoxicity within the nephron56. All segments of the

12

proximal tubule express endocytic apparatus, but there is notably fewer clathrincoated vesicles present in the S3 segment31. Megalin and cubilin have been
identified as the two major contributors involved in receptor- and clathrin-dependent
endocytosis occurring in the epithelial cells of the proximal tubules6,27,57,58. Megalin
and cubilin are co-expressed in absorptive epithelium of small intestines, renal
proximal tubules, the visceral yolk sac and the placental cytotrophoblast32.

Megalin
Megalin, a 600 kDa transmembrane protein with a large extracellular portion, was
first discovered in 1982 by Kerjaschki and Farquhar6.

Part of the low-density

lipoprotein family, megalin is the crucial driving component to aid in uptake of filtered
plasma proteins58. Megalin is a highly conserved protein expressed on the apical
surface of renal proximal tubules that contains a large extracellular domain (4,398
amino acids) built up with three different types of domains57. One of these domains
is responsible for the pH dependent release of ligands in the endosomal
compartments. Megalin has a single hydrophobic transmembrane segment (23
amino acids) and a smaller intracellular domain (209 amino acids). The N-terminal
domain of megalin recruits clathrin components to the plasma membrane to initiate
the early phases of endocytosis27. Many ligands have been identified for megalin
including

vitamin

D-binding

protein,

vitamin

A/retional-binding

protein,

β2-

microglobin, α1-microglobulin and albumin57. Fanconi syndrome has been
associated with megalin deficiency in the renal proximal tubule of patients leading to
increased albuminuria57. Conditional knockout of megalin in the proximal tubules led
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to increased levels of albuminuria when compared to control mice in an
unchallenged state11.

Cubilin
Cubilin, a smaller 460 kDa protein residing on cell surfaces, co-expresses with
megalin on the apical surface of epithelial cells to recognize and bind glomerular
filtrates like albumin found in the lumen of the proximal tubule6. Cubilin is tethered to
the plasma membrane containing many different domains that binds a variety of
ligands. Cubilin expression patterns mimic megalin in coated pit endocytic vesicles
and the membrane-recycling pathway. It has also been visualized in lysosomes.
Significant proteinuria has been identified in patients suffering from ImerslundGräsbech syndrome. Two Finnish families in which the disease is prevalent present
with mutations in the cubilin gene57. Like megalin deficient mice, cubilin deficient
mice display high levels of albuminuria. Mice lacking both cubilin and megalin
display even higher levels of albuminuria11.

Renal transcytosis
Uptake of excess albumin by renal proximal tubules has been well documented for
over 30 years, but more recent data reveals that albumin travels across the
basolateral membrane of proximal tubules for resorption back into the blood stream.
Thus, albumin no longer only has the fate of being internalized and degraded by the
lysosome as initially suspected. The blood reclaims albumin in a process known as
transcytosis. Albumin is internalized via the megalin-cubilin complex by receptor14

mediated endocytosis into clathrin-coated vesicles. Upon internalization, acidification
of the endosomes occurs causing the release of albumin from the megalin-cubilin
complex. Acidification is the vital step that allows albumin to bind to FcRn within the
endosomal sorting compartment. The megalin-cubilin complex is recycled back to
the apical membrane, while albumin binds to the FcRn receptor at low pH and is
transported back into the circulation at the basolateral membrane of renal proximal
tubules31.

FcRn
Jones and Waldmann discovered FcRn in 1972. There are two distinct binding sites
on FcRn for albumin and IgG with a low binding affinity at normal physiological pH,
but this binding affinity increases at acidic pH (<6.5). FcRn is expressed on vascular
endothelium, epithelial cells of small intestine, liver, spleen, lung, neutrophils,
monocytes, dendritic cells (DCs) and the renal proximal tubules. FcRn is a
heterodimer comprised of myosin heavy chain class I-like heavy chain and β2microglobulin. This molecule preserves the half-life of albumin by transporting
albumin across membranes59. Mutation or deletion of FcRn lowers the serum halflife of both albumin and IgG60,61.
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TLR4 and diabetic nephropathy
TLR4
Toll-like receptor 4 (TLR4), an evolutionarily conserved family of cell receptors, is
part of the innate immune system which reacts to pattern recognition receptors:
pathogen-associated molecular patterns (PAMPs) and danger-associated molecular
patterns (DAMPs)62. Upon activation by PAMPs or DAMPs, TLR4 recruits adapter
molecules including myeloid differentiation primary response gene 88 (MyD88)dependent

and

TIR-domain-containing

adapter-inducing

interferon-β

(TRIF)

independent pathways to elicit immune responses activating downstream pro- or
anti-inflammatory signaling pathways63,64. Transcription factors NF-κB and interferon
regulator factor 3 (IRF3) are activated to release cytokines and chemokines. TLR4 is
expressed in a variety of cells in the kidney including the proximal tubules,
podocytes, mesangial cells, DCs, lymphocytes and macrophages64.

TLR4 and diabetic nephropathy
Activation of TLR4 in response to the events of renal inflammation has been
observed in multiple different kidney injury models including ischemia/reperfusion,
obstructive

uropathy,

tubulointerstitial

nephritis,

nephrotoxicity

and

diabetic

nephropathy63,64. TLR4 deficient mice had significantly less albuminuria, renal
dysfunction, activation of NF-κB and infiltration of interstitial macrophages than wild
type (WT) mice in response to streptozotocin (STZ) induced diabetic nephropathy63.
Additionally, high glucose induced activation of NF-κB in proximal tubule cells. In
clinic, TLR4 is highly expressed in patients with diabetic nephropathy65-67. Overall,
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there is strong evidence that lack of TLR4 attenuates inflammatory responses and
prevents the development of diabetic nephropathy63,68.

1.4 – Introduction to CD13
Tissue structure, expression and function of CD13
CD13 (150 kDa), aminopeptidase N, is a cell surface, type II membrane bound, zincdependent metalloprotease shown to be involved in angiogenesis, inflammation and
receptor-mediated endocytosis. This seven-membrane protein is composed of a
short cytoplasmic tail, a transmembrane spanning region and a large extracellular
portion where the catalytic domain resides functions in both enzyme-dependent and
-independent mechanisms (Figure 1.1)69,70.

CD13 is highly expressed on cells of the myeloid lineage and on activated
endothelial cells found in the brain, liver, intestine and kidney. Further, CD13 acts as
an important mediator for monocytic/endothelial cell adhesion71. Like megalin, cubilin,
FcRn and TLR4, CD13 is highly expressed on the apical surface of epithelial cells in
the proximal tubules (Figure 1.2).

CD13 is involved in various physiological processes including peptide cleavage,
signal transduction, angiogenesis and cell adhesion70. Since CD13’s enzymatic site
is sterically restricted; CD13’s catalytic activity is zinc-dependent and favors neutral
N-terminal amino acids on oligopeptides72. Recent x-ray crystallographic analysis of
CD13 revealed that an eight-peptide residue loop alters the conformation to regulate
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various processes by providing substrate-specificity, contributing to CD13’s vast
distinct activities73.

CD13 regulates various vital normal physiological functions including the processing
of peptide hormones, such as angiotensin III and IV74, neuropeptides crucial in pain
response75 and chemokines involved in inflammation and angiogenesis73,76. Further,
CD13 influences cell adhesion, migration and endocytic processes70,71,77,78. CD13 is
a receptor for various mammalian coronaviruses79,80. Within the kidney it is a wellcharacterized marker that cleaves neutral amino acids from peptides and is sorted to
the apical membrane of epithelial cells found in the proximal tubule81. Interestingly, a
primary isolation protocol of proximal tubules has used CD13 as a marker to identify
epithelial cells of the kidney82.

Global CD13 deficient mouse
To discover the various functions of CD13, our lab generated a global CD13 null
transgenic mouse (CD13KO). CD13 contains 20 exons that make up the seven
domains ranging in size from 18 to 205 amino acids. CD13KO mice were generated
by deleting exons 4 through 13 of the exon region of CD13, eliminating the catalytic
domain in addition to extracellular subunits as confirmed by PCR69. Global CD13KO
mice show no overt phenotypic differences until challenged.
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CD13 and inflammation
Inflammation is an important physiological process that becomes activated in
response to infection or injury. The body detects cellular changes at the site of injury
and recruits circulating monocytes present in the blood stream that are home to
important chemoattractants to help resolve the infection or injury by creating an
inflammatory environment83. This infiltration of monocytes heavily relies on adhesion
molecules on both patrolling monocytes and endothelium lining the injury84,85.
Previous data from the lab demonstrated CD13 as an important regulator of
inflammatory cell trafficking. Upon injury CD13 becomes activated on epithelial cells
that allows for the recruitment of circulating peripheral blood monocytes. Through
homotypic adhesion between CD13 expressed on monocytes and the activated
endothelial cells, inflammatory cells enter the site of infection to resolve injury. This
phenomenon was demonstrated in models of hindlimb ischemia, myocardial
infarction and thigolycolate peritonitis86-88.

CD13 and endocytosis
Preliminary data in the lab as well as others have shown that CD13 regulates
clathrin-mediated endocytosis, suggesting it plays a role in fundamental aspects of
receptor-mediated endocytosis77,89,90. CD13 mediates internalization of antigens in
various receptor-mediated, dynamin-dependent endocytic receptors found in DCs.
DCs lacking CD13 took up ovalbumin and transferrin more efficiently than WT DCs.
CD13 is shown to co-internalize in DCs, but was not shown to co-immunoprecipitate
with antigen receptors77. CD13 also mediated TLR4 endocytosis. Immunofluorescent
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analysis confirmed that CD13 was internalized into dynamin+ and Rab5+ endosomes
after stimulation91. It was hypothesize that CD13 may interact with these important
endocytic components to regulate uptake of filtrates like albumin that are passing
through the lumen of the proximal tubules.

CD13 and TLR4
Previous data from the lab indicated that CD13 negatively regulates TLR4 endocytic
signal transduction in inflammation. After lipopolysaccharide (LPS), a PAMP,
stimulation DCs become activated and CD13 co-internalizes with TLR4, CD14 and
dynamin into early endosomes. TLR4 signals in two distinct pathways: (1) via
MyD88 pathway after ligation of PAMPs or DAMPs to activate the NF-κB proinflammatory pathway92 or (2) endosomal signaling activating TRIF/ TLR4 adaptor
protein (TRAM) pathway to activate IRF3 and further downstream anti-inflammatory
cytokines93. The MyD88 pathway is activated independent of CD13 expression.
Upon internalization of TLR4 via dynamin-dependent mechanisms, there is
activation of IRF3 and the upregulation of target genes. CD13KO response to
inflammation is skewed towards IRF3 anti-inflammatory pathway. Thus this data
indicates that CD13 is crucial for balancing the innate immune response by
preserving inflammatory equilibrium of both pro-inflammatory and anti-inflammatory
responses after injury91.
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1.5 – Aims of the study
The multifunctionality of CD13 prompts further investigations to determine how
CD13 would react in a model of kidney injury. Recent findings from the laboratory
strongly suggest CD13 to be highly involved in inflammatory processes as well as
acting as an important mediator of endocytosis. The first goal of the study aimed to
identify the structural components required for adhesion of peripheral monocytes to
activated endothelial through the use of chimeras generated by previous lab
members. The second goal of the thesis was to look at a model of renal injury since
data from the lab suggested CD13 and TLR4 have been shown to be intrinsically
related. The investigation sought to determine how CD13KO mice would behave in
response to diabetic nephropathy as it has previously been demonstrated that lack
of TLR4 has an improved phenotype in renal injury models. Upon further evaluation
of the results, the focus shifted towards understanding how CD13 regulates renal
endocytosis and whether uptake of more albumin was beneficial to overall renal
prognosis. Next the study strived to determine how renal proximal tubular epithelial
cells would behave in a model of diabetic nephropathy to identify how CD13
performs in a renal injury model. Finally, to evaluate clinical implications for CD13,
UPJO urine samples were collected to determine their efficacy and reliability as
renal injury biomarkers.
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1.6 – Figures and Legends
FIGURE 1.1 – CD13 PROTEIN STRUCTURE.
FIGURE 1.2 – LOSS OF CD13 EXPRESSION IN KIDNEYS OF CD13KO MICE.
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Figure 1.1 – CD13 Protein Structure.
Modified from94.
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CD13 is expressed in the renal
proximal tubules
WT

CD13KO

Dapi CD13 40X

Figure 1.2 – Loss of CD13 expression in kidneys of CD13KO mice.
Immunofluorescence of CD13 in the cortex of WT and CD13KO kidneys. CD13 stains
epithelial cells within the proximal tubules.
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Molecular Mechanisms Regulating CD13-Mediated Adhesion
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The contribution to this publication included inserting the full length mouse and
human CD13 constructs as well as both chimera constructs into C33a and WEHI
78/24 by infecting these cells with media containing virus expressing the constructs
from amphotrophic phoenix packaging cells. Further contributions included
verification of CD13 expression by western blot and flow analysis and completion of
all in vitro adhesion assays.

2.1 – Introduction
Inflammation is a highly regulated and coordinated activity heavily relying on many
different cells types to respond to infection or injury. First, the site of injury releases
cytokines to signal for monocytes to insinuate injury, infection or insult within its’
environment. These monocytes circulate throughout the body in the blood, bone
marrow and spleen. Searching for infection or injury, monocytes bind to activated
endothelium that has released vital distress signals. The inflammatory trafficking
26

model is well known, however the precise mechanisms that control trans-endothelial
migration of the monocyte to injury site via adhesion remains poorly understood88,95.

CD13 is highly expressed on many tissues regulating various physiological
mechanisms. More recently, it has been shown that CD13 is crucial in the trafficking
of immune cells, as CD13 is highly expressed on cells of myeloid lineage in addition
to endothelial cells at sites of inflammation. Monocytic CD13 becomes activated by
crosslinking antibodies to induce CD13 phosphorylation, leading to CD13-dependent
homotypic monocyte/endothelial adhesion71,96. Further in vivo work from the lab
demonstrates that at baseline CD13KO mice have no overt phenotypic differences,
but in response to injury less infiltrating myeloid population reach the site of injury
after various forms of ischemic injury86,97. For instance, after permanent coronary
occlusion, CD13KO mice have fewer infiltrating myeloid population after injury
affecting cardiac repair86. Further evidence in a different model of injury indicates
that lack of CD13 affected reperfusion and muscle regeneration after hindlimb
ischemia due to a reduction in infiltrating myeloid cells97.

In this study, a thioglycollate-induced peritonitis model was utilized to confirm altered
trafficking contributes to phenotypes found in other models of ischemia. Furthermore,
domain specific CD13 chimeras were generated to verify that the C-terminus of
CD13 regulated monocyte/endothelial cell adhesion and myeloid trafficking.
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2.2 – Materials and methods
Animals
FVB CD13KO mice were generated at the Gene Targeting and Transgenic Facility at
the University of Connecticut Health Center69. All mice were housed in pathogenfree conditions with 12 h light/dark cycle and controlled temperatures at the
University of Connecticut Health Center animal facilities. All procedures were
performed in accordance with the Institutional and Office of Laboratory Animal
Welfare guidelines.

Thioglycollate-induced sterile peritonitis
Male mice were age matched 6-8 weeks of age and were injected with 1 mL of 3%
thioglycollate intraperitoneally. After 48 hours, peritoneal lavage cells were collected
for flow cytometric analysis.

Flow cytometry
After collection of cells from peritoneal lavage, spleen, bone marrow and peripheral
blood, cells were stained with a cocktail of antibodies at 4°C for 30 min (anti-CD45.1PE, anti-F4/80-FITC, anti Gr-1-APCe780, anti-CD3/CD19/NK1.1/Ly6G-AF700, antiCD11c-PECy7 and anti-CD11b-Pacific blue and UV live dead dye (to eliminate dead
cells)). Flow cytometry was performed on LSRII (Becton Dickinson) and data was
analyzed with FlowJo software (Tree Star). Live/dead cells were negatively gated for
T-cells, B-cells, NK cells and Ly6G+ cells to eliminate lymphocytes, natural killer cells,
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and neutrophils respectively. CD45+ cells were analyzed for macrophages (F4/80+
CD11b+), DCs (CD11c+ CD11b+), inflammatory monocytes (Gr-1hi CD11b+) and
reparative monocytes (Gr-1lo CD11b+). C33a and WEHI 78/24 cells were stained
with 1:250 human CD13 monoclonal antibody 452 followed by 1:1000 goat anti-rat
Alexa488 secondary and then analyzed for human CD13 by flow cytometry.

Generation of chimeras
Generation of mouse/human (M/H) chimeric molecule was previously done in the lab
by using human CD13 TOPO vector that was digested stepwise with NotI and EcoRI
to eliminate the N-terminal half of the construct. The NotI construct was not
conserved between mouse and humans species. A mouse CD13 forward primer site
was designed to add the NotI site. After the creation of forward and reverse primers
for both the C-terminal and N-terminal half of the mouse cDNA, digestion was
performed. EcoRI and PmeI site eliminated the C-terminal half of the human CD13
construct to generate human/mouse (H/M) CD13 chimera. Human, mouse, M/H and
H/M constructs/chimeras cDNAs were cloned into the pcDNA/V5/GW/D-TOPO
(Invitrogen) according to manufacturer’s instruction88.

Cell lines
U937, a human leukemic monocytic cell line; C33a, a human cervical cancer cell
line; WEHI 78/24, a mouse monocytic cell line, and Phoenix amphotrophic
packaging cell line (Orbigen) were used in this study. C33a and WEHI 78/24 were
cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Life Technologies)
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supplemented with 10% fetal bovine serum (HyClone) and 1% penicillin (100
units/mL)-streptomycin (100 units/mL) (Life Technologies). U937 cells were cultured
in

Roswell

Park

Memorial

Institute

medium

(RPMI)

(Life

Technologies)

supplemented with 10% fetal bovine serum (HyClone) and 1% penicillin (100
units/mL)-streptomycin (100 units/mL) (Life Technologies). Phoenix amphotrophic
packaging cell lines were cultured with DMEM supplemented with 10% fetal bovine
serum (HyClone), 1% penicillin (100 units/mL)-streptomycin (100 units/mL) (Life
Technologies) and 1% non-essential amino acids (NEAA) (Life Technologies). All
cell lines were cultured at 37°C with 5% CO2.

Retroviral vector construction and infection
The V5 tagged chimeras and constructs were excised and cloned into retroviral
expression vector pBM-IRES-Puro. This vector was transfected into Phoenix
amphotrophic cell lines utilizing lipofectamine (Invitrogen). In one tube, 24 µg of DNA
vector was added into 1.5 mL DMEM media (no other components were added to
the media). In a different tube 60 µL lipofectamine was added in 1.5 mL DMEM. Both
tubes were incubated at room temperature for 5 min before combining the tubes.
After combination of DNA vector with lipofectamine, this was further incubated at
room temperature for 2 min. This mixture was then added to 50% confluent Phoenix
amphotrophic cells. After 4 h, the media was changed using DMEM containing fetal
bovine serum and penicillin-streptomycin. After 48 h, the media contains viral DNA
containing the vector expressing the constructs or chimeras. As a control, empty
vector (EV) virus was also generated. C33a were 50% confluent prior to infection
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with 10 mL virus stock containing 5 µg/mL polybrene, which neutralizes charge
repulsion between virions and sialic acid on cell surface. Viral containing media was
removed from C33a after 24 h and cells recovered for 48 h prior to enriching the
population with 2 µg/mL puromyocin selection (as determined by a kill curve) for
48 h88,96. For infection of non-adherent WEHI 78/24 cells, 1 x 105 cells were
resuspended in 5 mL virus stock in 15 mL conical tube and centrifuged at 800 g for
30 min at 32°C in the presence of 5 µg/mL polybrene. Cells were supplement in
standard DMEM with fetal bovine serum, antibiotics and L-glutamine for 48 h prior to
selection. Cells were enriched by puromyocin selection (1 µg/mL for 36 h).

Western blot
Cells were lysed in NP-40 lysis (1% NP-40, 150 mM sodium chloride (NaCl) and
50 mM Tris pH 8) buffer in the presence of protease inhibitors (5 mM sodium fluoride
(NaF), 1 mM sodium orthovanadate and a mini protease cocktail (Roche
Diagnostics)). Protein concentration was measured by bicinchoninic acid (BCA)
assay (Thermo Scientific) following manufacturer’s instructions. Samples were run
on 10% SDS-Page gel and transferred onto polyvinylidene fluoride (PVDF)
membrane. Membranes were blocked in 5% milk/tris-buffer saline tween (TBST) for
30 minutes and then incubated with primary antibody (mouse anti-human 452
1:1000 and 1:10,000 rat anti-mouse CD13) overnight at 4°C on a rocker. The next
day, blots are washed thrice with TBST and incubated with secondary antibody
(1:1000 goat anti-mouse horseradish peroxidase (HRP) and 1:5000 goat anti-rat
HRP). Samples were visualized with chemiluminescence using SuperSignal.
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Membrane was developed. Afterward the membrane was stripped for 10 minutes, it
was then blocked and probed for loading control, β-actin or glyceraldehyde 3phosphate dehydrogenase (GAPDH) (1:5000 dilution).

Quantitative adhesion assay
C33a were seeded (5 x 105) on 96 well tissue culture treated plates and grown to
confluency overnight. Monocytes (U937 or WEHI 78/24) were labeled with calcein
(0.5 µL/mL) for 30 min at room temperature in the dark. Monocytes or epithelial layer
is then crosslinked with 1 µg CD13 monoclonal crosslinking antibody 452 or IgG for
30 min at 37°C. Monocytes were incubated with C33a epithelial cells to allow for
adhesion. Unbound monocytes were extensively washed. Cells were lysed and
fluorescence was measured at 485/530 (Biorad, Model 680) after being transferred
to a black bottom plate. Each condition was assayed in triplicate.

Adoptive transfer of splenic myeloid cells and mCD13 WEHI 78/24
Differentially labeled with fluorescent dyes PKH67 (green) and PKH26 (red) (SigmaAldrich, St. Louis, MO), WT and CD13KO splenic myeloid cells or WEHI 78/24
transfectants were adoptively transferred via tail vein following thioglycollate injection.
mCD13 WEHI 78/24 cells were either untreated or treated with 1 mg of Shapiro Lab
13 (SL13) monoclonal blocking antibody. After 48 h, peritoneal lavage cells were
analyzed by flow cytometry.
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Statistical analysis
Results are presented as mean ± standard error of mean (SEM). Statistical analysis
was performed using unpaired, two-tailed t test on excel. Differences were
considered significant at p < 0.05.

2.3 – Results
Previous data from the lab proved that CD13 acts as a homotypic adhesion
molecule regulating monocyte/endothelial adhesion in vitro and that mice deficient in
CD13 had different inflammatory cytokine profiles after injury, indicating that CD13
may regulate inflammatory processes through its adhesive properties. A model of
thioglycollate peritonitis was used to evaluate this possibility. Inflammatory
monocytes in the bone marrow, spleen, peripheral blood and peritoneal exudates in
WT and CD13KO mice were assessed by flow cytometry. The CD11b+Gr1hi proinflammatory monocyte population decreased by nearly 70% in CD13KO animals
compared to WT, however there was no difference in the CD11b+Gr1lo reparative
monocyte. Furthermore, DCs and macrophage populations were also lowered in
CD13KO peritoneal lavage when compared to WT lavage (Figure 2.1 A). Remarkably,
inflammatory monocytes population was significantly elevated in the blood of
CD13KO mice (Figure 2.2 B).

Next, a gain-of-function approach was used to evaluate if CD13 expression offers
improved trafficking of monocytes and to confirm that infiltration of myeloid cells into
the peritoneal cavity is a CD13 specific event. Adoptive transfer of CD13-expressing
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monocytic WEHI 78/24 (mCD13; red) or control cells EV (EV; green) was added into
the circulation of WT animals induced with thioglycollate peritonitis. More mCD13expressing cells resided in the peritoneal cavity when compared to EV control
(Figure 2.2 A). Similarly, pretreatment of mCD13-expressing WEHI 78/24 with antiCD13 blocking monoclonal antibody (SL13; green) resulted in reduction of infiltrating
cells into the peritoneal cavity (Figure 2.3 A). These cells were not cleared by the
immune system, as equal numbers were present in the peripheral blood of
unchallenged animals (Figure 2.2 B, Figure 2.3 B).

To investigate if binding of CD13 is species and domain specific, chimeras were
generated using mouse and human constructs of CD13. CD13 is a type II protein
composed of seven domains; domain I contains a short cytosolic tail, followed by
domain II which is the membrane spanning domain and is highly conserved among
species and finally the extracellular portion of CD13 is composed of domains III-VII
(Figure 2.4 A). The extracellular domain is site to the enzymatic functions of CD13.
Two different chimeras were constructed, one comprising the murine CD13 Nterminus (including domains I-V and 50% of domain VI) fused to human CD13 Cterminus (including 50% of remaining domain VI and domain VII), designated as M/H
(Figure 2.4 D, F). The reciprocal chimera H/M was generated comprising the human
CD13 N-terminus and C-terminus of murine CD13 (Figure 2.4 E, F). Both endothelial
cells (C33a) and monocytic cells (WEHI 78/24) were infected with these clones.
Flow cytometric analysis confirmed that exogenous human CD13 was expressed on
human construct in addition to M/H chimera (Figure 2.5 A). Western blot analysis
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confirmed that exogenous mouse CD13 was expressed on mouse construct in
addition to H/M chimera (Figure 2.5 B).

Next, a functional assay was utilized to determine if the C-terminal domain was
mediating homotypic monocyte/endothelial cell adhesions. Previously, reports
indicated that basal adhesion of primary CD13KO macrophages to endothelial cells is
diminished and that CD13 activation on either monocytes or macrophages induces
adhesion in vitro69,71,96. In vitro adhesion assay utilizing the engineered cell lines
were designed. Activating anti-human monoclonal antibody 452 was used to verify
that the effects of trafficking obtained with the chimeric monocytic cell lines in vivo is
due to CD13 homotypic adhesion. The various CD13-expressing monocyte cell lines
were added to adherent epithelial cells C33a (expressing EV control or human
CD13) activated with antibody 452 or isotype control (Figure 2.6 A). Monocytes
expressing human CD13 and M/H CD13 mediated homotypic adhesion to human
CD13 positive epithelial cells. Relatedly, activation of the U937 monocytes with 452
or isotype control allowed for adhesion with epithelial cells expressing human CD13
or M/H CD13 (Figure 2.6 B). Comparably, activation of WEHI 78/24 M/H CD13 with
human CD13 monoclonal antibody 452 induced adhesion in epithelial cells
expressing total human CD13, as well as the chimera M/H, albeit at decreased
levels (Figure 2.6 C). These in vitro assays indicate that the C-terminal domain of
CD13 mediates homotypic monocyte/endothelial cell adhesion.
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Finally, the objective was to identify which domain was responsible for cellular
trafficking in response to inflammation. Similar to previous experiments, differentially
labeled cells with CD13-expressing monocyte lines or EV control were intravenously
injected into WT mice followed by thioglycollate injection. Initial experiments by flow
cytometry, confirmed that WEHI 78/24 expressing H/M chimera trafficked better to
the peritoneal lavage than EV WEHI 78/24 (Figure 2.7). Flow analysis revealed that
labeled peritoneal cells in the lavage were markedly higher for cells expressing H/M
CD13 chimera compared to EV or M/H CD13 chimera (Figure 2.8). Importantly, the
percentage of cells in circulation of other chimeras and EV control remained the
same. These results indicate that the C-terminal domain is responsible for
inflammatory cell trafficking.

2.4 – Discussion
Originally, CD13 was shown to be a marker of myeloid cells, where it is expressed
by varying degrees on myeloid progenitors and their differentiated progeny98. More
investigations in the lab demonstrated that CD13 is highly expressed on myeloid cell
subsets expressing CD8+ DCs where it mediates receptor-mediated antigen uptake
leading to T cell activation77. Further studies identified CD13 is highly expressed on
monocytes and may act as an important adhesion molecule after injury as shown in
models of both myocardial infarction and hindlimb ischemia86,97. Intriguingly, despite
the ratios of infiltrating cells being altered in both tissues types, myeloid cells were
differentially affected, indicating that myeloid cell trafficking patterns might be injuryand tissue-specific95 and that CD13 may command these trafficking phenotypes.
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This study utilized an injury model of thioglycollate-induced peritonitis to validate that
CD13 is an important regulator of cellular trafficking in vivo. Furthermore, the study
also wanted to identify the specific domain responsible for mediating adhesion.

Previous studies have identified CD13 as a species specific receptor for a subtype of
human coronaviruses, and this activity does not affect its enzymatic activity80. CD13
was first identified to have various enzyme-dependent functions like cleaving neutral
amino acids from the terminus of other small molecules, as well as peptides in the
renin-angiotensin system and intestinal dietary peptide99-101. More recent studies on
CD13 have also demonstrated that CD13 has important implications beyond its
enzymatic activities, identifying CD13 as a molecule that mediates homotypic
adhesion between monocytic and endothelial cells71. This study demonstrated the
importance of CD13 in monocyte-endothelial cell adhesion and trafficking by utilizing
various models including thioglycollate-induced peritonitis in addition to gain-offunction adhesion assays with cells expressing mouse CD13 or treated with blocking
mouse CD13 antibody.

The C-terminal domain of CD13 has been identified as an important receptor for
group 1 coronaviruses each of which has a unique species-specific binding site for
CD13102,103. Relatedly, the study found that CD13 dependent adhesion is also
species specific. Through the creation of chimeric expression constructs of the Nand C-terminal domains of human and mouse CD13 in both epithelial cells and
monocytes, it was shown that the C-terminal half mediates adhesion on cells
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expressed on both the monocytes and the endothelial layer. In vitro functional
assays as well as adoptive transfer studies of differentially labeled cells expressing
mixed chimeras in vivo showed that the C-terminal region of CD13 is crucial for
homotypic adhesion between endothelial cells and monocytes. Further studies will
conclude whether specific regions that dictate virus host range in various
coronaviruses also determines species-specific adhesion.

Subsets of various monocytes exist that are responsible for either inflammation or
reparation. Depending on the microenvironment of infection, inflammatory
monocytes (Gr-1high/Ly6Chigh, mouse) have two main fates after arriving at the site of
infection in that they either differentiate into activating or inhibitory macrophage and
DCs subsets. These inflammatory monocytes are elevated in the circulation in
response to injury and infiltrate injury sites more readily than reparative
monocytes95,104. Reparative monocytes (Gr-1lo CD11b+) reside in tissues and
replenish tissue macrophages or DCs to aid in the healing process104,105. The
present study found that CD13 is more highly expressed on the inflammatory
monocyte subset and that migration of these inflammatory cells is skewed in CD13KO
mice after thioglycollate-induced peritonitis. Despite these advancements in the field,
the differential trafficking to tissues after injury remains unknown and it will require
more investigation to identify the precise mechanism that regulates inflammatory
trafficking.
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2.5 – Figures and Legends
FIGURE 2.1 – ALTERED

INFLAMMATORY CELLS IN

CD13KO

MICE AFTER THIOGLYCOLLATE

PERITONITIS.

FIGURE 2.2 – CD13

EXPRESSING MONOCYTES TRAFFIC TO PERITONEAL CAVITY AFTER

INJURY.

FIGURE 2.3 – BLOCKING CD13

EXPRESSION INHIBITS MONOCYTES TRAFFICKING TO

PERITONEAL CAVITY AFTER INJURY.

FIGURE 2.4 – CD13 SPECIES AND DOMAIN-SPECIFIC CONSTRUCT.
FIGURE 2.5 – CD13 EXPRESSION IN CHIMERA CONSTRUCTS.
FIGURE 2.6 – THE C-TERMINAL DOMAIN IS RESPONSIBLE FOR HOMOTYPIC CELL ADHESION.
FIGURE 2.7 – EXPRESSION OF CD13 ON MONOCYTES IS VITAL FOR CELL TRAFFICKING INTO
INFLAMED PERITONEUM.

FIGURE 2.8 – THE C-TERMINAL

HALF OF

CD13

TRAFFICKING INTO INFLAMED PERITONEUM.
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Figure 2.1 – Altered inflammatory cells in CD13KO mice after thioglycollate
peritonitis.
(A) Flow cytometric quantification of percent of infiltrating inflammatory monocytes
(Gr-1hi CD11b+), reparative monocytes (Gr-1lo CD11b+), macrophages (F4/80hi
CD11b+) and DCs (CD11chi CD11b+) based on gated CD45+ cell population
collected from peritoneal lavage. (B) Flow cytometric quantification of percent
inflammatory monocytes (Gr-1hi CD11b+) in peripheral blood. Error bars represent
mean ± SEM for WT (n=8) and CD13KO (n=8) mice; *p<0.05.
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Figure 2.2 – CD13 expressing monocytes traffic to peritoneal cavity after injury.
(A) Differentially labeled murine monocytic WEHI 78/24 cells with either mouse
CD13 (mCD13-red) or EV control (EV-green) were adoptively transferred into
thioglycollate administered WT mice. Cells expressing CD13 trafficked to peritoneal
lavage as analyzed by flow cytometry. (B) Peripheral blood expressed similar
percentages of labeled monocytes. Data represents average of 3 independent mice
experiments. Error bars represent mean ± SEM for WT (n=5) and CD13KO (n=5)
**p<0.01.
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Figure 2.3 – Blocking CD13 expression inhibits monocytes trafficking to
peritoneal cavity after injury.
(A) Differentially labeled murine monocytic WEHI 78/24 cells with untreated mouse
CD13 (mCD13-red) or SL13 blocking antibody treated mouse CD13 (SL13 tx CD13green) were adoptively transferred into thioglycollate administered WT mice. Cells
expressing CD13 trafficked to peritoneal lavage as analyzed by flow cytometry. (B)
Peripheral blood expressed similar percentages of labeled monocytes. Data
represents average of 3 independent experiments. Error bars represent mean ±
SEM for WT (n=5) and CD13KO (n=5) mice; ***p<0.001.
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Figure 2.4 – CD13 species and domain-specific construct.
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CD13 construct. (B) Full length human CD13 and (C) full length mouse CD13. (D, F)
M/H chimera construct denotes CD13 chimera containing mouse CD13 at the Nterminal half and human CD13 at the C-terminal half and (E, F) H/M chimera
construct denotes human CD13 at the N-terminal half and mouse CD13 at the Cterminal half.
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Figure 2.5 – CD13 expression in chimera constructs.
(A) Histogram of C33a and WEHI 78/24 expressing human CD13 and M/H chimera
with anti human 452 CD13 monoclonal antibody as analyzed by flow cytometry. (B)
Western blot analysis of C33a and WEHI 78/24 expressing mouse and H/M CD13
constructs. Data represents average of two independent experiments.
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Figure 2.6 – The C-terminal domain is responsible for homotypic cell adhesion.
(A) EV and human CD13 expressing C33a cells were treated with activating anti
human CD13 452 monoclonal antibody or control IgG. Calcein labeled WEHI 78/24
expressing all constructs were added to the monolayer and homotypic adhesion was
measured as fluorescence intensity at O.D. 485 nm and 530 nm. A significant
increase in adhesion was observed in WEHI 78/24 expressing human CD13 and
M/H CD13. (B) The human monocytic cell line highly expressing CD13, U937, was
calcein labeled and cross-linked with 452 or IgG. U937 cells were incubated with
C33a expressing all constructs and adhesion was measured. C33a expressing
human CD13 and M/H CD13 showed significant adhesion with 452 activated U937
cells. (C) Comparably, WEHI 78/24 EV, human CD13 and M/H CD13 activated with
452 or IgG was added to all constructs of C33a monolayer. C33a expressing human
CD13 and M/H CD13 showed significant homotypic adhesion to WEHI 78/24
expressing human CD13 and M/H CD13. Data represents ratio of relative
fluorescence unit (RFU) measured upon activation with 452 to control IgG. Data
represents average of 3 independent experiments ran in triplicate. Error bars
represent mean ± SEM; **, p<0.01.
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Figure 2.7 – Expression of CD13 on monocytes is vital for cell trafficking into
inflamed peritoneum.
Equal number of WEHI 78/24 cells transfected with H/M (CD13; red) and EV (EV;
green) were injected into WT mice after thioglycollate-induced peritonitis. Data
represents average of three independent experiments. Error bars represent mean ±
SEM for WT (n=5) mice; *p<0.05; **, p<0.01.
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Figure 2.8 – The C-terminal half of CD13 in monocytes is vital for cell
trafficking into inflamed peritoneum.
Equal number of WEHI 78/24 cells transfected with H/M (CD13; red) and M/H
(CD13; green) were injected into WT mice after thioglycollate-induced peritonitis.
More WEHI 78/24 expressing H/M chimera trafficked to peritoneal lavage as
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average of three independent experiments. Error bars represent mean ± SEM for
WT (n=5) mice; *p<0.05.
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Chapter 3
CD13 is a novel regulator of renal tubular
endocytosis

________________________________
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3.1 – Introduction
CKD develops in response to a variety of different insults and conditions including
trauma, sepsis, toxicity, cardiovascular disease and diabetes mellitus3,4. Of the 26
million patients affected yearly in the United States, approximately 1.8 million of
these are ultimately treated for ESRD by renal replacement therapy involving kidney
transplant, hemodialysis or peritoneal dialysis. Over time the kidney slowly
deteriorates due to complications from hypertension, diabetes or congenital
abnormalities1. Currently, there has been minimal progress toward limiting the
progression of renal deterioration despite implementation of the most aggressive
treatment options, which provide only limited protection to the nephron.

Numerous physiological pathways are disrupted throughout disease progression that
cumulatively contributes to irreversible renal injury and failure. In a healthy kidney,
the glomerulus filters albumin and other low molecular weight proteins and the
proximal tubules reabsorb these filtrates by endocytosis via the megalin/cubilin
receptor complex6,8-11. Impairment of either glomerular or tubular function leads to
albuminuria, promoting even further cellular dysfunction34,41. Urinary albumin triggers
pro-inflammatory and pro-fibrotic mechanisms which further damages renal
structures35,106.

One of the major sources of CKD in the United States is diabetic nephropathy, which
results from complication of diabetes mellitus. About 20% of patients with type 1 or
type 2 diabetes develop diabetic nephropathy within 10 to 20 years after diabetic
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onset4,12-14. Hyperglycemia attacks renal microvasculature leading to injury of
various kidney cells found in the glomerulus and proximal tubules12,14. Increased
glucose levels leads to damage at the basolateral membrane of proximal tubules.
Increased glucose filtration at the glomerulus leads to overload, resulting in
increased filtrate exposure at the proximal tubules14. However, the exact
pathophysiology and molecular pathways that lead to renal failure caused by
hyperglycemia remains unknown, albeit growing insight into studying disease
progression. To induce diabetic nephropathy in this study, mice were treated with a
low dose of STZ for five consecutive days. Mice develop overt diabetes within three
weeks and signs of diabetic nephropathy like albuminuria within five weeks after
STZ treatment2.

Recently, it was discovered that TLR4 is activated in response to renal events
observed in multiple different kidney injury models including diabetic nephropathy.
TLR4 deficient mice had improved renal function, significantly less albuminuria, and
decreased activation of NF-κB and infiltration of interstitial macrophages in
comparison to WT mice in response to STZ induced diabetic nephropathy63. In
humans, TLR4 is highly expressed in patients with diabetic nephropathy65-67. Overall,
there is strong evidence that lack of TLR4 attenuates inflammatory responses and
prevents the development of diabetic nephropathy63,68.

CD13 is a cell surface, membrane-bound, metallopeptidase expressed on various
myeloid cells as well as the apical surface of renal proximal tubule cells where it was
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found to cleave neutral amino acids from dietary peptides70. Importantly, recent
findings demonstrate that CD13 regulates endocytosis of immune regulator TLR4 in
DCs and promotes pro-inflammatory signal transduction in response to tissue injury.
PAMPs or DAMPs bind to macrophages and DCs, inducing TLR4 downstream
release of cytokines. Macrophages and DCs deficient in CD13 signal towards antiinflammatory pathways87,91, suggesting that CD13 synchronizes the balance
between pro-inflammatory and anti-inflammatory signaling.

In the proximal tubules of the kidney, receptor-mediated endocytosis is crucial for
resorption and metabolism of substances found in the lumen coming from the
glomerular filtrate. Megalin and cubilin have been identified as the two major
contributors involved in receptor- and clathrin-dependent endocytosis occurring in
the epithelial cells of the proximal tubules6,27,57,58. Following internalization,
molecules from the plasma membrane are either recycled back to the surface in
recycling endosomal compartments, sorted to the degradation pathway via late
endosomes and lysosomes or returned to the circulation by transcytosis31,51,55.
Acidification of the endosomal sorting compartment allows for the release of albumin
from the megalin/cubilin receptor and the subsequent binding to the FcRn receptor.
FcRn facilitates the transportation of albumin towards the basolateral membrane of
the proximal tubule where it is released back into circulation31. Patients with
mutations in the megalin or cubilin receptor, present with high urinary albumin
levels107; indicating that alterations within the endocytic machinery of the proximal
tubules affects urinary protein levels and subsequent renal injury. Importantly, like
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megalin and cubilin, CD13 is highly expressed on the brush border of renal proximal
tubules. Furthermore, recent data from the lab suggest that CD13 is a novel
regulator of clathrin-mediated endocytosis that controls internalization of a number of
receptors including transferrin, mannose and TLR477,89,90.

Since CD13 had been shown to intricately regulate TLR4 signaling pathways, it was
hypothesized that CD13 would regulate TLR4 signaling in response to renal injury. It
was also proposed that CD13 might inhibit receptor-mediated endocytosis of
glomerular filtrate in proximal tubular epithelial cells.

3.2 – Materials and Methods
Mice
Global CD13KO mice were generated at the Gene Targeting and Transgenic facility
at the University of Connecticut Health Center69. All mice were housed in pathogenfree conditions with 12 h light/dark cycle and controlled temperatures at the
University of Connecticut Health Center animal facilities. All procedures were
performed in accordance with the Institutional and Office of Laboratory Animal
Welfare guidelines.

Diabetic Nephropathy
Age matched, 6 to 8 week old C57/Bl6 mice were fasted for 6 h prior to injection of
50 mg/kg of STZ in 1 M sodium citrate buffer, pH 4.5. Intraperitoneal injection was
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given for 5 consecutive days to induce diabetes (n=14)108. Sham mice received
injection of sodium citrate buffer only (n=5). Mice were housed in metabolic cages at
basal time points and every 4 weeks after treatment for 24 h to collect urine.

Glucose tolerance test
Blood glucose was measured after 16 h of fasting using an Accu-Chek® glucose
monitor (Roche Diagnostics) from tail vein blood. Glucose was intraperitoneally
injected (20% glucose solution, 1 g/kg) and blood glucose was measured at 15, 30,
60 and 120 min after injection109.

Electron microscopy
All processing took place at the Electron Microscopy Core at the University of
Connecticut Health Center. Kidney tissue was fixed by whole body perfusion with
2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer, pH 7.4. Tissues were further
fixed with osmium tetroxide. Postfixation tissues were dehydrated in graded ethanol
solutions. Tissues were embedded in epoxy resins and 70 mm sections were cut on
the Leica ultramicrotome, mounted on 200 mesh copper grids and counterstained
with uranyl acetate and lead citrate. Images were taken on Hitachi H-7650
transmission electron microscope.
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Measurement of albumin and IgG clearance
Mice were given a single intravenous dose of 2 mg FITC-labeled albumin (Sigma,
A9771) or 0.5 mg of FITC-labeled IgG (Sigma, F9636). Retro-orbital blood was
collected 12, 24 and 48 h after injection. Samples were frozen at -80 °C and thawed
at time of assay. Quantities of fluorescence were measured spectrofluorimetrically;
baseline serum was used to subtract background fluorescence.

Albumin overload
WT and CD13KO mice 7 weeks old were given daily intraperitoneal injections of
bovine serum albumin (BSA) (Sigma A-9430) dissolved in sterile saline starting at
2 mg BSA/g body weight with increasing doses of 2 mg BSA/g body weight until day
5 and a final injection was given on day 8 of 10 mg BSA/g body weight (n=9). Sham
mice received injections of saline (n=3). Mice were placed in individual metabolic
cages overnight on day 8 for 24 h urine collection and harvested on day 9 for further
analysis49,50.

Histology
Kidneys and pancreas were harvested and fixed in 10% formalin (Fisher Scientific)
overnight at 4°C and dehydrated in 70% ethanol prior to processing and embedding.
Paraffin-embedded sections were de-paraffinized in histoclear or xylene and then
washed in graded ethanol prior to rehydration. For Periodic acid-Schiff (PAS) stain,
slides were treated with 0.5% periodic acid (Sigma, P7875) for 15 min, rinsed in
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distilled water, stained with Schiff’s reagent (Rowley Biochemicals, SO-429) for
15 min. Nuclei was stained with hematoxylin for 1 min. Antigen retrieval was
performed using sodium citrate buffer. Tissues were blocked for 1 h and incubated
with primary antibody overnight at 4 °C (CD13 1:1000, Megalin 1:1000, FcRn 1:100).
Slides were washed and the appropriate secondary antibody was added for 1 h.
After the final wash, nuclei were counterstained with DAPI in mounting media
(Vectashield, Vector Laboratories).

Cell culture of primary proximal tubule epithelial cells
Cortex of the kidney was removed, minced and digested in 15 mL collagenase
(0.0125 g in 50 mL plain DMEM/F12 media) for 45 min at 37°C with 5% CO2. After
digestion cells were treated with red blood cell (RBC) lysis buffer for 5 minutes,
followed by filtration with a 40 µm strainer before being plated onto plastic dishes
(1x106 cells in a 6 cm dish or 2x106 cells in a 10 cm dish). DMEM/F12 media
(Corning CellGro, 10-092-CV) was supplemented with 2.5% fetal bovine serum, 1%
penicillin (100 units/mL)-streptomycin (100 units/mL) (Life Technology) and 1%
NEAA (Life Technology). Cells were cultured in an incubator with 5% CO2 at 37°C.
Media was changed every 3 days maintaining 1/3 of the original media.

Western blot
Cells were grown to confluency and lysed with 1% NP-40, 25 mM Tris-hydrochloric
acid (HCl) (pH 7.4), 150 mM NaCl, 10 µg/mL aprotinin, 10 µg/mL leupeptin, 50 mM
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β-glycerophophate, 1 mM sodium fluoride (NaF) and 100 mM NaOrhovanidate.
Protein concentration was determined by BCA protein assay kit according to
manufacturer’s protocol (ThermoFisher Scientific). For immunoprecipitation, 500 µg
of protein lysate was incubated overnight at 4°C with 2 µg antibody (IgG, CD13 or ptyrosine). Protein G beads were added to lysate and incubated for 2 h, washed and
resuspended. Lysate was denatured for 5 min at 100°C, cells were run on 10%
SDS-Page gel (4% for megalin). Gels were transferred onto PVDF membranes.
Blots were blocked with 5% BSA/TBST and incubated with primary antibody
(1:10,000 CD13, 1:1000 E-cadherin, 1:1000 megalin, 1:5000 β-actin, 1:1000 FcRn)
overnight at 4°C, washed and incubated with appropriate secondary for 1 h at room
temperature. Bands were visualized with ECL and developed.

Flow cytometry
For primary cells, media was collected and cells were treated with Tryp LE (Gibco,
12605-010) for 10 min and pelleted. For kidneys, the entire kidney was minced and
treated with collagenase for 1 h at 37°C. Cells were treated with RBC lysis buffer
and filtered. For Annexin/PI (Life technologies, V13242) staining protocol was
followed as described in manual. For albumin uptake, cells were first stained with
1:20 CD26 APC (Biolegend, 137807) and then fix/permeabilized (BD, 554741) per
manufacturer’s protocol. Cells were stained with 1:20 FITC albumin (R&D, IC1455G).
Flow analysis was run on LSR-II and data was analyzed with FlowJo software (Tree
Star).
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Measurement of serum and urine
All urine was collected using metabolic cages. Mice were individually housed in
metabolic cages for 24 h and urine was collected throughout this period. Diabetic
mice were placed in the cage at basal, 8, 12, 16 and 20 weeks post STZ treatment.
AO mice were placed in metabolic cages on day 8. Serum was collected by cardiac
puncture. Albumin enzyme-linked immunosorbent assay (ELISA) (Bethyl, E90-131),
urinary creatinine (R&D, KGE005) and serum creatinine (Caymen, 700460) were
used to analyze albuminuria and GFR.

Statistical analysis
Results are represented as mean ± SEM. Statistical analysis was performed using
unpaired, two-tailed t test analysis using Microsoft Excel. Differences were
considered significant at p < 0.05.

3.3 – Results
CD13KO mice have decreased albuminuria 20 weeks after STZ treatment
To directly investigate the interaction of CD13 in renal injury, diabetic nephropathy
was induced by injecting mice with STZ (or sham) for five consecutive days into WT
and CD13KO mice. Mice were harvested 20 weeks after the last injection. Weight
gain was assessed every four weeks. Overall weight gain was diminished in STZ
treated animals compared to controls, but no overall difference was observed
between WT and CD13KO mice (Figure 3.1). Additionally, the ratio of kidney weight
57

to the body weight decreased in STZ treated animals, but again there was no
difference between WT and CD13KO animals (Figure 3.1). The pancreas is the first
targeted organ during diabetic development, as the Islets of Langerhans found in the
beta cells are destroyed and incapable of releasing insulin in response to STZ
treatment. To rule out the pancreas as the underlying reason for identifying
differences in diabetic kidneys, pancreatic histology was evaluated and glucose
tolerance tests were performed. After STZ treatment, pancreatic beta cells were
destroyed and surrounding architecture of the pancreas was altered as visualized by
hematoxylin and eosin stain (Figure 3.2). STZ led to glucose intolerance in diabetic
animals as they were incapable of returning blood glucose levels back to fasting
baseline levels within two hours after intraperitoneal injection of glucose (Figure 3.3).
There were no observed and functional differences between the pancreas of WT
and CD13KO after STZ treatment. Four months after the induction of diabetes kidney
function was evaluated by serum creatinine. There was a decline in kidney function
in diabetic WT and CD13KO animals compared to sham mice (Figure 3.4)
Furthermore, there was increased urinary albumin excretion in diabetic kidneys 8, 12,
16 and 20 weeks after diabetic onset compared to sham treated animals.
Interestingly, total 24 h albumin excretion rate was significantly higher in WT STZ
treated mice than CD13KO mice 20 weeks after the induction of diabetes (Figure 3.4).

CD13KO mice maintain normal architecture of proximal tubule brush border
Next, the integrity of cortical kidney sections was evaluated by PAS stain. Tubules
were dilated, nuclei were shedding into the proximal tubules and there was overall
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sclerosis of the glomerulus in both WT and CD13KO kidneys 20 weeks after STZ.
Sham kidneys display normal characteristics and architecture with intact brush
border staining (Figure 3.5). Trichrome stain of STZ treated animals reveals a slight
increase in fibrosis in WT animals at 20 weeks when quantified with ImagePro Plus
software (Figure 3.6). Electron microscopy was further utilized to assess
morphological differences at high magnification of both the glomerulus and the
proximal tubule. First, an evaluation of the glomerular structure in WT and CD13KO
animals was performed; as it has been determined that glomerular injury is a major
contributor to albuminuria. Initial glomerular anatomy revealed no stark differences
between WT and CD13KO animals, and upon further evaluation of slit diaphragms
overall structure remains mostly intact, but disruption is evident in both WT and
CD13KO glomerulus. This ultimately leads to leaky filtration of proteins like albumin
(Figure 3.7). Finally, proximal tubule integrity was assessed to determine if
differences in albuminuria between WT and CD13KO mice was due to differences in
proximal tubule structures. The integrity of the brush border revealed stark visual
differences between WT and CD13KO proximal tubules. Brush border remained
intact and normal in CD13KO tubules, while the brush border of WT tubules were
partially destroyed and broken down (Figure 3.8). Additional evaluation of electron
microscopy in the proximal tubules showed intact endocytic vesicles. Interestingly,
quantification of endocytic vesicles by electron microscopy near the brush border
surface revealed that CD13KO mice had significantly more vesicles than WT mice
(Figure 3.9). Overall, there is decreased albuminuria in CD13KO mice. This appears
to be independent of altered responses to STZ treatment specifically within the
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pancreas or glomerulus, as glucose levels and glomerular histology was similar in
WT and CD13KO animals. Instead, CD13KO proximal tubules had intact brush
borders and increased endocytic vesicles, indicating that differences in albuminuria
levels is likely due to differential response to damage in the proximal tubules.

Lack of CD13 increases uptake of albumin by proximal tubules
In an effort to uncover the mechanism of proximal tubule uptake, an in vitro model
was utilized to identify CD13’s role in albumin uptake in proximal tubules. It is known
that isolated primary proximal tubular epithelial cells quickly lose expression of
important proximal tubular markers after early passages including CD13 and
megalin. Isolated primary proximal tubule epithelial cells expressed proximal tubule
markers megalin and E-cadherin in addition to CD13 at low passage (Figure 3.10).
The proximal tubule receptors megalin and cubilin are positive mediators of albumin
uptake. Previously it has been shown that megalin surface expression and
internalization is regulated by phosphorylation6,27,57. To identify the possibility of
CD13 regulating albumin uptake, it was first determined if CD13 is activated in
response to albumin. WT primary proximal tubule epithelial cells were treated with
1% BSA for 0, 5, 15, 30, 60 and 120 min and then lysed. Lysate was
immunoprecipitated with IgG or p-Tyrosine (CD13 activation site) and then probed
for CD13 to determine specific activation of CD13. A dose response with increasing
length of treatment was observed indicating that BSA activates CD13 (Figure 3.11).
Furthermore, uptake of leaky albumin from the glomerulus is vital and occurs at the
proximal tubules. With increasing doses of FITC-albumin, CD13KO primary proximal
60

tubule epithelial cells more efficiently took up albumin than WT primary proximal
tubule epithelial cells as determined by flow cytometric analysis (Figure 3.12). CD13
is a negative regulator in receptor-mediated, dynamin-dependent endocytosis of
albumin in the proximal tubules.

CD13 co-localizes with FcRn in proximal tubules
Filtrates that traverse the glomerular filtration barrier are normally reabsorbed in the
proximal tubules by endocytic processes. Internalized substances are either
degraded by lysosomes or returned back into the bloodstream by transcytosis. Next,
it was essential to determine if CD13 and megalin co-localize since megalin is a
crucial mediator of albumin internalization. Immunofluorescence staining reveals that
megalin and CD13 are both expressed in the brush border, but are distinctly
separate. Megalin did not co-immunoprecipitate with CD13 upon further analysis
(Figure 3.13). Another known regulator of albumin is FcRn, aiding in the transcytosis
of albumin back into the bloodstream after uptake of albumin by the megalin-cubilin
complex. FcRn binds albumin at low luminal pH after its release from the megalincubilin complex. Interestingly, FcRn and CD13 do co-localize at the brush border of
the proximal tubule, however the two proteins do not co-immunoprecipitate.
Additionally, the two proteins co-localize in vesicles inside the proximal tubules
(Figure 3.14). To determine if CD13 regulated transcytosis of albumin, the half-life of
albumin in WT and CD13KO mice was evaluated after injection of a single
intravenous dose of FITC-labeled albumin. CD13KO mice reclaimed greater
quantities of albumin than WT mice 12 and 24 h after injection, but levels equalized
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after 48 h (Figure 3.15). There was no difference in the half-life of IgG between WT
and CD13KO mice as expected as this is regulated by the glomerulus and not the
proximal tubules (Figure 3.15)60.

Primary proximal tubule epithelial cells undergo necrosis in response to high albumin
doses
Reduction of urinary protein levels is known to be therapeutically beneficial, however
various studies indicate that proteinuria-induced lysosomal overload underlies
mechanisms leading to cell damage31,40,49,110. CD13KO proximal tubules take up
albumin more efficiently than WT proximal tubules, but it was uncertain if this offered
protection to the renal proximal tubules. To investigate this phenomenon, WT and
CD13KO primary proximal tubule epithelial cells were serum starved overnight and
treated with increasing doses of BSA. Upon collection of in vitro primary proximal
tubule epithelial cells, the cells were stained with annexin and PI and then quantified
by flow cytometry for total apoptosis and necrosis, respectively. No observed
difference was visualized between cells positive for apoptosis or double positive for
apoptosis and necrosis marker 24 or 48 h after treatment (Figure 3.16). When
evaluating necrosis in primary proximal tubule epithelial cells, there was a strong
time and dose dependent response for both WT and CD13KO cells (Figure 3.16).
Despite their ability to take up more albumin, CD13KO primary proximal tubule
epithelial cells had equivalent levels of necrosis when compared to WT cells
indicating that high levels of circulating fragmented albumin might be harmful to
renal proximal tubules.
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AO leads to increase in albuminuria and less albumin uptake by proximal tubules in
WT mice
Albuminuria is a hallmark of kidney disease and disease progression that occurs
once the glomerular filtration barrier is damaged and proximal tubules endocytic
machinery becomes saturated and can no longer meet the demands of filtrate
uptake. Numerous studies have indicated that renal damage is exacerbated due to
increasing levels of albumin at the proximal tubules, however the exact mechanism
remains unknown. Thus, an in vivo model of AO was utilized to assess the direct
effects of increased albumin on kidney injury (Figure 3.17). Serum creatinine, a
measure of overall kidney function, was significantly elevated in mice treated with
high levels of albumin (Figure 3.18). Albumin creatinine ratio was no different
between WT and CD13KO shams, but was significantly higher after AO. WT mice
developed significantly more albuminuria compared to CD13KO mice, similar to what
was observed in diabetic mice (Figure 3.18). Kidneys were harvested for flow
analysis to determine if CD13KO proximal tubules took up more albumin than WT
proximal tubules. AO led to increased uptake of albumin in both WT and CD13KO
proximal tubules compared to sham animals. Additionally, there was significant
increase in the amount of albumin uptake in CD13KO proximal tubules in sham and
AO mice (Figure 3.19).

63

No increase in renal necrosis or apoptosis in acute AO model
To determine if increased uptake by CD13KO proximal tubules leads to protection of
the nephron, renal pathology was evaluated by PAS stain in addition to total
apoptosis and necrosis by flow analysis. PAS stain revealed no gross damage to
structural integrity after AO in either WT or CD13KO kidneys. Proximal tubules further
displayed normal integrity of the brush border and the glomerulus displayed normal
characteristics (Figure 3.20). Further analysis was done by flow cytometry to
determine if overload led to more necrosis and apoptosis. Overall there was no overt
difference in apoptotic cells between sham and overload as expected by lack of
difference in the phenotype as observed by histological sections. Further there was
a slight increase in cells that displayed characteristics of both apoptosis and
necrosis after AO, albeit no significant difference (Figure 3.21). Those cells that had
undergone necrosis were also no different between sham and overload. Perhaps,
kidney cells can be exposed to high levels of albumin for extended periods of time
before sublethal damage caused by albumin leads to overt renal injury.

3.4 – Discussion
Diabetic nephropathy is a complication that arises many years after the onset of
diabetes mellitus. Chronically elevated blood glucose levels damages glomerular
structures. Furthermore, advanced glycation endproducts circulating in the blood
stream causes a variety of cellular damage in both the glomerulus and the proximal
tubules111. Endocytosis of advanced glycation endproducts by the megalin receptor
causes toxicity in the tubular cells112,113. CD13 is a multifunctional molecule that is
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highly expressed on the apical surface of renal proximal tubules. Recent studies in
the lab, found that CD13 controls pro-inflammatory signal transduction by regulating
immune regulation of TLR4 and its subsequent signaling91. Deletion of TLR4
protects mice against renal injury associated with diabetes by alleviating the effects
of albuminuria to reduce tubulointerstitial fibrosis and inflammation66. It was
hypothesized that lack of CD13 would limit the progression of renal damage by
altering TLR4 responses. However, the initial findings on decreased albuminuria
shifted directions of the project to pursue how albuminuria contributes to and
promotes further renal injury. In response to STZ induced diabetic nephropathy,
albumin endocytosis via the proximal tubules is altered in the absence of CD13
leading to less albuminuria in CD13KO mice. However, this appeared to be
independent of altered responses to STZ treatment specifically within the pancreas
or glomerulus, as glucose levels and glomerular histology was similar between WT
and CD13KO animals.

Since there was no significant differences observed in pancreatic and glomerular
structures, it was speculated that decreased albuminuria in CD13KO mice may be
due to differential proximal tubule injury. The proximal tubule has been identified as
the single most important regulator of taking up albumin and other filtrates from the
lumen via endocytic mechanisms by epithelial cells, the most populous cells in the
kidney30. Many kidney disorders first manifest with injuries at the proximal tubules as
these cells orchestrate the rate of attrition of renal function. Since CD13 is highly
expressed on the apical surface of proximal tubules, it was postulated that absence
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of CD13 at the proximal tubules increases the uptake of albumin in a STZ model of
renal disease. The ultrastructure of proximal tubules in diabetic kidneys was
evaluated; it was found that CD13KO mice had intact brush borders in comparison to
WT brush borders, which were extensively damaged after 20 weeks of diabetes.
Upon further evaluation of the proximal tubules by electron microscopy, more
endocytic vesicles were visualized in CD13KO proximal tubules in comparison to WT
tubules. Furthermore, CD13 was activated in a time-dependent manner in response
to albumin. Importantly, in vitro analysis revealed that primary proximal tubule
epithelial cells lacking CD13 internalized more albumin in a dose dependent manner
when compared to primary proximal tubule epithelial cells expressing CD13.

Megalin and cubilin are known endocytic regulators found in the apical membrane of
the proximal tubules. Previous investigations have shown that these two molecules
co-localize in the brush border of renal proximal tubules and act in unison to take up
glomerular ultrafiltrate proteins114. Increased albumin uptake in CD13KO cells
suggested a relationship between CD13 and the megalin/cubilin receptor complex.
However, immunofluorescence determined megalin and CD13 were distinctly
separate on the surface of the proximal tubule. Unlike cubilin and megalin, CD13
and megalin did not co-localize. Previous investigations have examined the
association of CD13 and other receptors including the mannose receptor91.
Macrophages lacking CD13 were capable of taking up more ovalbumin compared to
macrophages expressing CD13. Furthermore, CD13 was not co-localized with the
mannose receptor, but did co-internalize into early endocytic vesicles77. Perhaps,
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CD13 is acting similarly on the megalin receptor by mediating recycling of the
megalin/cubilin receptor back to the membrane.

Upon internalization albumin has two main fates: being degraded by lysosomes or
being returned back into the circulation by transcytosis regulated by the FcRn
receptor31. FcRn is internalized into endocytic vesicles along with albumin bound to
the megalin/cubilin complex. Acidification of these endosomal vesicles transfers the
albumin molecule from the megalin/cubilin complex to FcRn where albumin is then
brought to the basolateral membrane. Albumin is then returned to the circulation and
megalin/cubilin is recycled back to the apical surface of proximal tubules. FcRn
preserves the lifespan of albumin by mediating it’s transport across the basolateral
membrane of renal proximal tubules60. However, recent investigations have
suggested that FcRn is not just responsible for the transcytosis of albumin, but may
also regulate the uptake of albumin found in the lumen of renal proximal tubules as
well60,115,116. Interestingly, others have proposed that binding of albumin to the
megalin/cubilin complex results in albumin being transported only to the lysosome
for degradation57,117. Furthermore, crystallographic evaluation of FcRn at acidic (pH
6.5) and basic pH (pH 8.2) indicates that a conformational change at pH 6.5
stabilizes the binding of albumin115. The lumen of the of the proximal tubule is
slightly acidic with a pH around 6.8, making it very plausible that FcRn takes up
albumin from the lumen of proximal tubules and brings it to the basolateral surface
where albumin then undergoes transcytosis. CD13 co-localizes with FcRn in the
brush border of renal proximal tubules as well as in vesicles found in the most
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basolateral parts of these epithelial cells. Remarkably, CD13KO mice have an
increased albumin half-life indicating that CD13 might be mediating transcytosis of
albumin back into the bloodstream. This phenomenon possibly contributes to
decreased urinary albumin levels observed in CD13KO mice.

It has been well established that albuminuria is an early predictor of renal injury and
that origin of proteinuria is due to a combination of problems in glomerular filtration
and proximal tubular reabsorption118,119. Increase internalization of proteins by the
proximal tubules is thought to mediate inflammation and fibrosis that ultimately
contributes to the death of the nephron and renal failure120. Previous studies have
found that overloaded proximal tubules become activated and express proinflammatory cytokines to induce the apoptotic pathway121. Other studies have
focused on how glomerular proteinuria injures proximal tubules122,123. There has
been a strong emphasis in identifying the precise molecular pathway that leads to
renal injury in response to protein overload.

Decreased albuminuria in CD13KO mice in a model of diabetic nephropathy and AO
offered a suitable model to study the deleterious effects of protein accumulation in
the urine. Initially, it was observed that CD13KO primary proximal tubule epithelial
cells took up more albumin than WT tubules. Further in vitro evaluation determined
that proximal tubules exposed to high levels of albumin were necrotic 24 and 48 h
after treatment. Yet, there was no difference between WT and CD13KO proximal
tubules as assessed by flow cytometry indicating that high levels of albumin cause
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sublethal injury to proximal tubular cells. Uptake of albumin did not offer any extra
protection to extremely high levels of albumin, which is toxic to proximal tubules.

To explore this concept in vivo an animal model of AO was utilized. Mice were
treated with increasing doses of albumin for 8 days and kidneys were harvested for
further analysis. Mice displayed decreased renal function as evaluated by serum
creatinine. Consistent with the data from the diabetic nephropathy mice, CD13KO
mice had decreased albuminuria which was due to increased uptake of albumin by
the proximal tubules as assessed by flow analysis. Despite the change in renal
function, histological analysis revealed no overt renal injury after AO in either WT or
CD13KO animals. Finally, flow analysis of apoptotic and necrotic markers was not
elevated after AO. Individuals with albuminuria inevitably develop ESRD indicating
that injury related to albuminuria takes years to develop. A constant exposure of high
albumin levels causes sublethal injury by activating inflammatory cytokines to
promote apoptosis.

In summary, these findings identify CD13 as a novel regulator of albumin
endocytosis in the proximal tubules. CD13KO proximal tubules more efficiently take
up albumin in comparison to WT proximal tubules as observed both in vitro and in
vivo. CD13 co-localizes with transcytosis receptor FcRn. CD13KO mice have
increased albumin half-life, indicating that CD13 negatively regulates FcRn
processes. Further, assessment of how albumin uptake relates to renal injury found
that the process of taking up more albumin had no overall effect on the death of
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proximal tubules. Finally, the use of an AO model suggests that nephron injury as a
result of albuminuria is an extensive process that takes years to accumulate.
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3.5 – Figures and Legends
FIGURE 3.1 – WEIGHT GAIN AND KIDNEY WEIGHT IN SHAM AND STZ TREATED ANIMALS.
FIGURE 3.2 – HISTOLOGY OF PANCREAS IN SHAM AND STZ TREATED MICE.
FIGURE 3.3 – GLUCOSE TOLERANCE TEST TO ASSESS PANCREATIC FUNCTION IN SHAM AND
STZ TREATED MICE.
FIGURE 3.4 – INCREASED

RENAL INJURY AND ALBUMINURIA IN MICE WITH DIABETIC

NEPHROPATHY.

FIGURE 3.5 – HISTOLOGY OF KIDNEY IN SHAM AND STZ TREATED MICE.
FIGURE 3.6 – QUANTITATIVE ANALYSIS OF FIBROSIS BY EXPRESSION OF COLLAGEN.
FIGURE 3.7 – ELECTRON MICROSCOPY OF GLOMERULUS AFTER 20 WEEKS STZ.
FIGURE 3.8 – ELECTRON

MICROSCOPY OF RENAL PROXIMAL TUBULES AFTER

20

WEEKS

STZ.
FIGURE 3.9 – QUANTIFICATION

OF ENDOCYTIC VESICLES IN PROXIMAL TUBULES AFTER

20

WEEKS OF DIABETIC NEPHROPATHY.

FIGURE 3.10 – WESTERN

BLOT ANALYSIS OF EXPRESSION OF PROXIMAL TUBULE MARKERS

IN PRIMARY PROXIMAL TUBULES.

FIGURE 3.11– PRIMARY

PROXIMAL TUBULES TREATED WITH

BSA

ACTIVATES

CD13

IN A

TEMPORAL MANNER.

FIGURE 3.12 – LACK

OF

CD13

INCREASES UPTAKE OF ALBUMIN BY PRIMARY PROXIMAL

TUBULES.

FIGURE 3.13 – LOCALIZATION OF MEGALIN AND CD13 WITHIN THE KIDNEY.
FIGURE 3.14 – LOCALIZATION OF FCRN AND CD13 WITHIN THE KIDNEY.
FIGURE 3.15 – CLEARANCE OF ALBUMIN AND IGG IN WT AND CD13KO MICE.
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FIGURE 3.16 – ANALYSIS

OF APOPTOSIS AND NECROSIS AFTER HIGH DOSE OF ALBUMIN IN

PRIMARY PROXIMAL TUBULES.

FIGURE 3.17 – ALBUMIN OVERLOAD MODEL.
FIGURE 3.18 – EVALUATION OF RENAL FUNCTION AND ALBUMINURIA IN MICE AFTER AO.
FIGURE 3.19 – QUANTIFICATION

OF IN VIVO ALBUMIN UPTAKE BY RENAL PROXIMAL TUBULE

CELLS AFTER AO.

FIGURE 3.20 – HISTOLOGY OF KIDNEY IN SHAM AND AO TREATED MICE.
FIGURE 3.21 – ANALYSIS OF APOPTOSIS AND NECROSIS AFTER AO IN PROXIMAL TUBULES.
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Figure 3.1 – Weight gain and kidney weight in sham and STZ treated animals.
(A) Body weight normalized to basal to assess weight gain in WT and CD13KO sham
or STZ treated animals. (B) Ratio of kidney weight and body weight. Data represents
mean ± SEM; n = 4 sham, n = 10 STZ; *, p<0.05; **, p<0.01; ***, p <0.001.
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Figure 3.2 – Histology of pancreas in sham and STZ treated mice.
Hematoxylin and eosin stain of formalin-fixed paraffin embedded pancreas to assess
gross architecture of pancreas. These are representative images of pancreas from
WT and CD13KO mice after 20-week sham or STZ treatment. The scale bar
represents 50 µm.
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Figure 3.3 – Glucose tolerance test to assess pancreatic function in sham and
STZ treated mice.
Blood glucose concentrations (mg/dL) during intraperitoneal glucose tolerance test
(1 g/kg) following 16 h fast for (A) sham and (B) STZ treated animals at basal and
seven weeks post injection. Data represents mean ± SEM; n = 5 sham, n = 15 STZ;
***, p <0.001.
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Figure 3.4 – Increased renal injury and albuminuria in mice with diabetic
nephropathy.
(A) Serum creatinine was assessed in WT and CD13KO mice after 20 weeks of sham
or STZ treatment. (B) 24 h urinary albumin levels were measured at basal, 8, 12, 16
and 20 weeks after STZ treatment by ELISA. Data represents mean ± SEM; n = 4
sham, n = 13 STZ; *, p <0.05.
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Figure 3.5 – Histology of kidney in sham and STZ treated mice.
PAS stain of formalin-fixed paraffin embedded kidneys. These are representative
images of kidneys of WT and CD13KO mice after 20 weeks sham or STZ treatment.
The scale bar represents 50 µm.
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Figure 3.6 – Quantitative analysis of fibrosis by expression of collagen.
(A) Trichrome stain was used to evaluate overall fibrosis in STZ WT and CD13KO
kidneys 20 weeks after treatment. (B) Ten fields per kidney were analyzed and
quantified with Image Pro Plus and Prism Graphpad software for total collagen
(blue). Data represents mean ± SEM; n = 5.
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Figure 2
A

WT

CD13KO

B

Figure 3.7 – Electron microscopy of glomerulus after 20 weeks STZ.
Glomerular morphology was evaluated by electron microscopy. (A) The upper panel
depicts a representative image of an entire glomerulus (1000x). The scale bar
represents 10 µm. (B) The lower panel shows the slit diaphragms of the podocytes
(15,000x). The scale bar represents 500 nm.
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WT

CD13KO

Figure 3.8 – Electron microscopy of renal proximal tubules after 20 weeks STZ.
These are representative images of electron microscopy of proximal tubules 20
weeks after STZ treatment. The brush border is shown with the white arrows. Brush
border is disrupted in WT proximal tubules, while CD13KO maintains brush border
integrity. The scale bar represents 2 µm.
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Figure 3.9 – Quantification of endocytic vesicles in proximal tubules after 20
weeks of diabetic nephropathy.
(A) Endocytic vesicles are observed by electron microscopy. Endocytic vesicles are
seen below the surface of the brush border (white arrows). The scale bar represents
500 µm. (B) Quantification of total vesicles from 10 different fields. Data represents
mean ± SEM; n = 1; *, p <0.05.
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In Vitro model - primary proximal tubule
epithelial cells

Figure 3.10 – Western blot analysis of expression of proximal tubule markers
in primary proximal tubules.
CD13 expression was evaluated in WT and CD13KO primary proximal tubule
epithelial cells by western blot analysis. CD13 is expressed only in WT primary
proximal tubule epithelial cells. E-cadherin, a marker for epithelial cells, is expressed
in both WT and CD13KO cells as confirmed by western blot analysis. Megalin
expression is maintained after the first passage of primary proximal tubule epithelial
cells.
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Figure 3.11– Primary proximal tubules treated with BSA activates CD13 in a
temporal manner.
WT primary proximal tubule epithelial cells were serum starved overnight and
treated with 1% BSA for 0, 5, 15, 30, 60 and 120 min and lysed. The lysate was
immunoprecipitated with IgG or p-Tyrosine (CD13 activation site) and then probed
for CD13 to determine specific activation of CD13.
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Figure 3.12 – Lack of CD13 increases uptake of albumin by primary proximal
tubules.
WT and CD13KO primary proximal tubule epithelial cells were serum starved
overnight and treated with increasing doses of Albumin-FITC for 1 h. Cells were
harvested. Internalized albumin-FITC was evaluated by flow cytometry. Data
represents mean ± SEM; n = 3; *, p <0.05.
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Figure 3.13 – Localization of megalin and CD13 within the kidney.
(A) WT, unchallenged kidneys were co-stained with CD13 (red), megalin (green) and
DAPI (nuclear, blue). Megalin and CD13 are expressed on the apical surface of the
brush borders, but do not co-localize. The scale bar represents 10 µm. (B) Confluent
WT primary proximal tubule epithelial cells were lysed followed by IgG or CD13
immunoprecipitation from total protein extracts. Endogenous megalin did not coimmunoprecipitate with CD13.
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Figure 3.14 – Localization of FcRn and CD13 within the kidney.
(A) WT, unchallenged kidneys were co-stained with CD13 (red), FcRn (green) and
DAPI (nuclear, blue). FcRn and CD13 are co-localized on the apical surface of the
brush borders. The scale bar represents 10 µm. (B) Confluent WT primary proximal
tubule epithelial cells were lysed followed by IgG or CD13 immunoprecipitation from
total protein extracts. Endogenous FcRn did not co-immunoprecipitate with CD13.
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Figure 3.15 – Clearance of albumin and IgG in WT and CD13KO mice.
(A) After single intravenous dose of albumin-FITC into WT and CD13KO mice,
clearance of albumin was measured spectrophotometrically. (B) After single
intravenous dose of IgG-FITC into WT and CD13KO mice, clearance of albumin was
measured spectrophotometrically. For clearance data, serum fluorescence intensity
of FITC was measured. Data represents mean ± SEM; n = 3; *, p <0.05.
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Figure 3.16 – Analysis of apoptosis and necrosis after high dose of albumin in
primary proximal tubules.
WT and CD13KO primary proximal tubule epithelial cells were serum starved
overnight and treated with 0 mg/mL, 50 mg/mL or 100 mg/mL of BSA for 24 or 48 h.
Cells were harvested and stained for annexin (apoptotic marker) and PI (necrotic
marker). Total staining was measured by flow cytometry analysis for (A) annexin+
PI+ cells, (B) annexin+ cells and (C) PI+ cells. Data represents mean ± SEM; n = 3.
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Figure 3.17 – Albumin overload model.
WT and CD13KO mice aged 6-8 weeks were intraperitoneally injected with increasing
doses of BSA. Mice were harvested on day 9. Kidneys and serum were collected for
further analysis.
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Figure 3.18 – Evaluation of renal function and albuminuria in mice after AO.
(A) Serum creatinine at day 9 for sham and AO mice. (B) Albumin creatinine ratio for
24 h urine collection (Day 8 to Day 9) for sham and AO mice. Data represents mean
± SEM; n = 3 sham, n = 9 AO. **; p<0.01 ***; p <0.001.
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Figure 3.19 – Quantification of in vivo albumin uptake by renal proximal tubule
cells after AO.
Flow cytometric analysis of endocytosed albumin in CD26+ (proximal tubule) cells in
sham and AO mice 9 days after AO. Data represents mean ± SEM; n = 3 sham, n =
9 AO. *; p<0.05 ***; p <0.001.
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Figure 3.20 – Histology of kidney in sham and AO treated mice.
PAS stain of formalin-fixed paraffin embedded kidneys. These are representative
images of kidneys of WT and CD13KO kidneys 9 days after AO or sham treatment.
The scale bar represents 50 µm.
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Figure 3.21 – Analysis of apoptosis and necrosis after AO in proximal tubules.
WT and CD13KO kidneys were harvested. Total staining was measured by flow
cytometry analysis for (A) annexin+ PI+ cells, (B) annexin+ cells and (C) PI+ cells.
Data represents mean ± SEM; n = 3 sham, n = 9 AO.
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congenital urinary anomalies
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*Adapted from Journal of Pediatric Urology, Published November 28, 2015 (doi:
10.1016)
Proximal tubule proteins are significantly elevated in bladder urine of patients
with ureteropelvic junction obstruction and may represent novel biomarkers:
A pilot study

Claire Gerber1, Miriam Harel1,2, Miranda L. Lynch3, Katherine W. Herbst2, Fernando
A. Ferrer1,2, Linda H. Shapiro1,2
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Center for Vascular Biology, University of Connecticut Health Center, Farmington,
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4.1 – Summary
“PURPOSE: Ureteropelvic junction obstruction (UPJO) is the major cause of
hydronephrosis in children and may lead to renal injury and early renal dysfunction.
However, diagnosis of the degree of obstruction and severity of renal injury relies on
invasive and often inconclusive renal scans. Biomarkers from voided urine that
detect early renal injury are highly desirable due to their noninvasive collection and
their potential to assist in earlier and more reliable diagnosis of the severity of
obstruction. Early in response to UPJO, increased intrarenal pressure directly
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impacts the proximal tubule brush border. We hypothesize that single-pass, apicallyexpressed proximal tubule brush border proteins will be shed into the urine early and
rapidly and will be reliable non-invasive urinary biomarkers, providing the tools for a
more reliable stratification of UPJO patients.”124
“MATERIALS AND METHODS: We performed a prospective cohort study at
Connecticut Children's Medical Center. Bladder urine samples from 12 UPJO
patients were obtained prior to surgical intervention. Control urine samples were
collected from healthy pediatric patients presenting with primary nocturnal enuresis.
We determined levels of neutrophil gelatinase-associated lipocalin (NGAL), kidney
injury molecule 1 (KIM-1) (previously identified biomarkers), CD10, CD13 and CD26
(potentially novel biomarkers) by ELISA in control and experimental urine samples.
Urinary creatinine levels were used to normalize the urinary protein levels measured
by ELISA.”124
“RESULTS: Each of the proximal tubule proteins outperformed the previously
published biomarkers. No differences in urinary NGAL and KIM-1 levels were
observed between control and obstructed patients (p = 0.932 and p = 0.799,
respectively). However, levels of CD10, CD13 and CD26 were significantly higher in
the voided urine of obstructed individuals when compared to controls (p = 0.002, p =
0.024, and p = 0.007, respectively).”124
“CONCLUSIONS: Targeted identification of reliable, noninvasive biomarkers of renal
injury is critical to aid in diagnosing patients at risk, guiding therapeutic decisions
and monitoring treatment efficacy. Proximal tubule brush border proteins are reliably
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detected in the urine of obstructed patients and may be more effective at predicting
UPJO.”124

4.2 – Introduction
“Obstructive nephropathy is the underlying cause of ESRD in the majority of
pediatric patients. With an estimated prevalence of 1 in 500 births, UPJO is the
major cause of hydronephrosis and may lead to renal injury and early renal
dysfunction16. With the advent of widespread antenatal ultrasonography, many
cases of UPJO are identified prenatally in asymptomatic patients. The indications for
surgical intervention have become controversial, with some advocating initial
observation with serial imaging techniques and surgical intervention reserved for
patients with decreasing ipsilateral renal function and/or worsening drainage125.
While this strategy may minimize overtreatment in children who may prove to have
benign, self-limited hydronephrosis, other patients may suffer ongoing renal damage
during this period of nonoperative management.”124

“Mechanisms to assess the severity of damage caused by obstruction are decisively
lacking and primarily rely on serum creatinine, which remains unchanged until 50%
of nephron volume is lost17,126. Alternatively, differential renal function is determined
by nuclear scans such as radiolabeled mercapto-acetyl-triglycine (MAG3) that
measure the rate of kidney drainage (t1/2) and differential function. Generally, the
diagnosis of obstruction on MAG3 renography is based on a t1/2 greater than 20
minutes or poor differential renal function, while a t1/2 under 10 minutes is consistent
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with unobstructed drainage. Cases with a t1/2 between 10 and 20 minutes are
considered equivocal, which may be difficult to interpret clinically
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. Furthermore,

nuclear renography is costly, may require sedation in younger children, and often
requires repeat evaluation to assess progression of obstruction or deterioration in
renal function.”124

“Targeted identification of reliable urinary biomarkers would be invaluable for
diagnosing patients at risk for renal damage, guiding therapeutic decisions, and
potentially monitoring treatment efficacy. Currently, there are no reliable tests of
voided urine that can assist in risk stratification and decision-making in patients with
UPJO. While a number of promising urinary biomarkers have been proposed, their
efficacy varies with the etiology of renal damage, which undermines their utility126.
NGAL, interleukin-18 (IL-18), KIM-1 and cystatin C are proteins currently advocated
as promising biomarkers of acute kidney injury. Tubular synthesis of some of these
proteins is induced in response to injury (NGAL, IL-18, KIM-1), with additional
contributions from infiltrating inflammatory cells (IL-18, NGAL), while others
accumulate in the urine due to impaired reabsorption by damaged tubular epithelium
(NGAL, cystatin C)
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. While some studies have reported increased urinary NGAL

levels in children with UPJO and correlation of NGAL levels with differential renal
function, other studies have demonstrated that NGAL levels do not improve risk
prediction of progressive CKD128-131. While urinary KIM-1 levels were increased in
children with UPJO, KIM-1 levels were not elevated in adults with acute obstructive
nephropathy

secondary

to

nephrolithiasis130,132,
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and

urinary

KIM-1

levels

demonstrated only a weak diagnostic value for the detection of renal injury of various
etiologies133. Thus, while NGAL and KIM-1 may hold promise in the detection of
some forms of renal injury, further studies are necessary to investigate their potential
utility and to determine whether more reliable and consistent biomarkers may be
identified.”124

“An early effect of ureteral obstruction is increased pressure in the proximal tubules
causing distention, damage and shedding of proteins expressed on the apical
surface of the brush border epithelium19,134. Hydronephrosis progressively causes
cellular damage due to hypoxia, ischemia, stretching, production of reactive oxygen
species and fibrosis. Ultimately, this damage results in tubule cell death, tubular
atrophy, interstitial inflammation and collagen deposition, impairing the growth and
development of the obstructed kidney and causing compensatory enlargement of the
unaffected kidney19,134.”124

“Proteins can be secreted or shed into the urine from a number of cellular sources
and at various time frames following renal insult. Tissue injury invariably induces the
innate immune response and a concomitant increase in the extrarenal secretion of
cytokines and other proteins from infiltrating and resident inflammatory cells.
Impaired glomerular filtration resulting from tissue damage can allow release of
proteins that are normally trapped by the glomeruli into the urine. These high urinary
protein concentrations overwhelm the resorption capacity of the proximal tubule
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epithelium, further contributing to proteinuria. Finally, the expression of pro-healing
proteins is upregulated in response to injury126.”124

“In UPJO, destruction and shedding of the proximal tubule brush border proteins into
the urine is an early event19. Recent proteomic analyses of brush border lysates
from isolated human proximal tubules identified numerous highly abundant
proteins135,136. Of these, we identified three proximal tubule metallopeptidases
(CD10, CD13 and CD26) that are highly to moderately abundant, apically-expressed,
and have a single-pass transmembrane domain, reasoning that these will be more
readily shed early and rapidly from the proximal tubule epithelium into the urine and
may represent useful non-invasive urinary biomarkers.”124

In this study, we used a unilateral ureteral obstruction (UUO) model to identify the
reliability of CD13 as a biomarker in murine renal injury. Further, we sought to
evaluate the relative efficacy of the proximal tubule proteins CD10, CD13 and CD26
in predicting UPJO in pediatric patients when compared to the established, potential
biomarkers of kidney injury NGAL and KIM-1. We hypothesized that proximal tubule
markers will be predictive of identifying renal injuries due to UPJO.124

4.3 – Materials and Methods
Animal model - UUO
Six to eight week old C57/Bl6 WT mice were anesthetized with isoflurane gas and
shaved. Following a flank incision to expose the ureter, the right ureter was ligated
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with 8-0 nylon22,137. The side receiving ligation is referred to as the ligated kidney,
while the contralateral kidney is referred to as the unligated kidney. Animals’ tissue
was collected at Day 1, 2, 4, 3, 5, 7 and 10 after ligation. Micturated, unligated urine
was collected 20 min prior to harvest, while ligated urine was collected from pooled
urine above the ligation that collected in the renal pelvis (Figure 4.1).

Immunohistochemistry
For histological samples, kidneys were collected and fixed in 10% formalin (Fisher
Scientific) overnight at 4°C, followed by dehydration in 70% ethanol. Samples were
then processed and paraffin embedded at the University of Connecticut Health
Center Research Histology Core. Tissues were cut in thickness of 5-8 µm. For
hemoatoxylin and eosin stain, samples were rehydrated before staining. For
immunofluorescence, antigen retrieval was performed in a pressure cooker in pH 6.0
sodium citrate buffer (Sigma). Tissues were blocked in 5% BSA/PBS for 1 h at room
temperature. Sections were incubated with primary antibody at 1:1000 rat anti-CD13
(Shapiro Lab) in 5%BSA/PBS overnight in a humidity chamber. Samples were
washed the following day and probed with secondary antibody goat anti-rat in 5%
BSA/PBS. Nuclear was counterstained with hard mounting Vectashield containing
DAPI (Vector) and cover slipped. Images were taken on Zeiss Axioplan 2
microscope with AxioCam MRc software.
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Western blot
Protein was lysed in NP-40 lysis buffer containing a protease inhibitor cocktail,
sodium orthovanadate and NaF. Following lysis, sample concentration was
measured by BCA assay (ThermoScientific) according to manufacture instruction.
Samples were run on 10% SDS-Page gel and transferred onto PVDF membrane.
Membranes were blocked in 5% milk/TBST for 30 minutes at room temperature and
then incubated with 1:10,000 rat anti-CD13 (Shapiro Lab) primary antibody in 5%
milk/TBST overnight at 4°C on a rocker. The following day, the membrane was
washed and probed with secondary goat anti-rat HRP. Samples were visualized with
chemiluminescence using SuperSignal. Membrane was developed. Afterward the
membrane was stripped for 10 minutes and then probed for loading control, β-actin
(1:5000 dilution). Westerns were quantified using ImageJ software.

Collection of case and control patients
“After obtaining institutional review board approval, a prospective cohort study was
performed in patients with unilateral UPJO treated with open or robotic dismembered
pyeloplasty at Connecticut Children’s Medical Center between 2012 and 2014.
Surgical intervention was recommended based on MAG3 renography demonstrating
obstructed drainage or equivocal drainage time with decreased ipsilateral renal
function. Urine samples were obtained intraoperatively from the bladder by
cystoscopy or urethral catheterization.”124
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Collection and processing of urine samples
“Control urine samples were collected via clean catch from otherwise healthy
children presenting for primary nocturnal enuresis without any complicating urologic
or nephrologic anomalies. Patient demographics, radiographic imaging and
operative details were obtained from medical records. Written informed consent was
obtained from all patients.”124

“Urine samples were collected and stored at 4°C and aliquoted and stored within
24 h of collection at -80°C until urinalysis. Urinary creatinine was measured on the
day of urine collection at Connecticut Children’s Medical Center. Quantitative urine
analysis was performed using commercially available human NGAL, KIM-1, CD10,
CD13 and CD26 sandwich ELISA kits (R&D Systems). Each specimen was
analyzed in duplicate, and the concentration of the patient samples was determined
by using standard curve analysis upon generating a four parameter logistic curve-fit.
Urinary creatinine levels were used to normalize the urinary protein levels measured
by ELISA.”124

Statistical analysis
“Statistical analysis of biomarker performance proceeded along two tracks. First,
hypothesis tests were used to compare whether there were different levels of
biomarker between UPJO cases and controls. Second, we used logistic regression
models for the binary outcome of case status, where the predictor variable in the
model was the level of biomarker. For the hypothesis testing, Mann-Whitney U tests
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were used as a nonparametric robust alternative to t-tests; all tests were two-sided
with α = 0.05. In the logistic regression analyses, each biomarker was examined in a
univariate model as predictor for outcome. Significance of regression coefficients
was assessed at the 0.05 level. All analyses were performed in the statistical
software R138.”124

4.4 – Results
After ureteral ligation, damage to the kidney is visible in the cortical proximal
tubules30. Increased pressure within the kidney causes progressive loss of the brush
border in the proximal tubule. Further as injury length increases, there is extended
dilation and thinning of the epithelial cells lining the proximal tubules (Figure 4.2 A).
Interestingly, CD13 expression progressively decreases in the cortex of kidneys as
damage from UUO increases and accumulates in the lumen (Figure 4.2 B,C).

The progression of UUO leads to the shedding of CD13 from the proximal tubules
into the urine. CD13 levels were prominently increased in the urine of obstructed
kidney

compared to contralateral kidney urine at earliest time points following

ureteral ligation. The increase of CD13 seen in urine samples was suspected to
come from the brush border of proximal tubules found in the kidney. Indeed, upon
further evaluation, CD13 levels diminished in ligated kidneys compared to unligated
kidneys, suggesting that CD13 is being shed readily into the urine (Figure 4.3).
Remarkably, CD13 is being detected in very early stages of renal injury and may be
a predictive biomarker of obstructive renal injury.
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“The UPJO patient cohort consisted of 12 patients (8 males, 4 females) with a
median age of 42 months (range 4 – 240). All patients underwent successful
unilateral dismembered pyeloplasty, with bladder urine collected at the time of
surgery. Patient demographics and clinical parameters are displayed in Table 4.1.
The control group included 12 patients with primary nocturnal enuresis (5 males, 7
females) with a median age of 96 months (range 48 – 186). There was no significant
difference in age or gender between the two cohorts.”124

“Overall, no statistical differences were observed in the levels of the published
candidate biomarkers, KIM-1 and NGAL, between control and experimental groups
(Table 4.2, Figure 4.4). However, the urinary concentrations of CD10, CD13 and
CD26 were readily detected and significantly higher in samples from UPJO patients
when compared to control patient samples (p = 0.002, p = 0.024 and p = 0.007,
respectively, Table 4.2, Figure 4.5). In the logistic regression models, a positive
regression coefficient would indicate increasing levels of biomarker being associated
with higher probability of being a case compared to control. In our analyses, results
demonstrated that all three proximal tubule markers had positive coefficients
(indicating that increased levels of biomarker predict higher probability of UPJO),
with CD10 and CD26 achieving marginal and full significance (p = 0.086 and 0.050,
respectively). Neither NGAL nor KIM-1 were significantly associated with probability
of predicting obstruction, and KIM-1 had a negative fitted coefficient value (i.e.,
higher biomarker levels predicting absence of UPJO).”124
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“We investigated correlations between urinary protein levels and differential renal
function on MAG3 renography. No significant linear correlations were observed for
any of the five urinary proteins studied. We observed trends in the data suggestive
that increased levels of CD10 and CD26 are associated with decreased differential
renal function; however, the presence of some outliers in these small datasets
rendered interpretation of correlation values difficult. Based on Spearman rank
correlation tests, the correlation values were -0.28, 0.21, -0.07, 0.55, and -0.32 for
CD10, CD13, CD26, KIM-1, and NGAL, respectively, with associated p values
0.0408, 0.536, 0.842, 0.081, and 0.339.”124

4.5 – Discussion
“In our study, bladder urinary levels of the proximal tubule brush border proteins
CD10, CD13 and CD26 were significantly higher in patients with UPJO compared to
normal controls, while the levels of KIM-1 and NGAL were not significantly different
between UPJO patients versus controls. Furthermore, our murine model of UUO
validated CD13 as a strong predictor of renal injury. Our preliminary results suggest
that these novel proximal tubule proteins may prove to be useful biomarkers that are
more predictive of urinary tract obstruction.”124

“While there are many proteins expressed in the proximal tubules, CD10, CD13 and
CD26 are three highly abundant and single transmembrane brush border proteins
that have been previously mentioned as potential biomarkers. CD26 was identified in
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biochemically-fractionated urine from patients with renal injury, suggesting that it is,
indeed, shed into the urine and detectable139. Urinary levels of CD13 and CD10
have been implicated as potential indicators of early renal disease. Compared to
healthy controls, urinary levels of CD13 were found to be significantly elevated in
patients with glomerulonephritis, and elevated levels of urinary CD13 appeared to be
an indicator of very early tubular impairment140. Additionally, urinary excretion of
CD13 was found to be significantly higher in patients with diabetic nephropathy
compared to healthy controls141. Urinary levels of CD10 were demonstrated to rise
significantly after cardiac surgery, suggesting that urinary excretion of CD10 may be
an indicator of acute and impending renal damage following cardiac surgery142. The
precise mechanisms and utility of these proteins as urinary biomarkers have yet to
be fully elucidated.”124

“While other studies investigating potential urinary biomarkers often sample urine
from the obstructed renal pelvis, we chose to test bladder urine, because ideal
urinary biomarkers should be measurable in bladder urine. The need to obtain urine
from an obstructed renal pelvis in order to improve the sensitivity of the biomarker
would diminish the feasibility and utility of such biomarkers. While bladder urine is
diluted by the contralateral unobstructed kidney in patients with unilateral UPJO,
studies have shown that levels of specific proteins in voided urine of children with
UPJO can be elevated up to fourfold that in control patients, demonstrating the utility
of biomarkers even in bladder urine143,144. Furthermore, others have found that the
levels of other urinary marker proteins in children with unilateral UPJO were not
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significantly different in the voided versus obstructed renal pelvis urine, possibly due
to the lower creatinine excretion with reduced glomerular function of the obstructed
kidney, thus offsetting the dilution effect of the contralateral kidney in the bladder
urine145. This provides further support for the feasibility of detecting sensitive
biomarkers in bladder urine from patients with UPJO.”124

“We investigated the correlation between urinary concentrations of these proteins
with differential renal function and drainage time on MAG3 renography; however, no
significant linear correlations were identified. This is likely due to the small sample
size of our study and the presence of outliers in these small datasets, making any
potential correlations difficult to demonstrate. However, this also raises the
possibility that other potential measures of renal function or obstruction, such as
urinary biomarkers, may prove to be more sensitive than nuclear imaging. We are
not suggesting that nuclear renography should not be used in the evaluation of
congenital urinary tract obstruction, as this is arguably the best indicator of upper
urinary tract obstruction currently available. However, we believe that other potential
modalities that might be more sensitive and less invasive should be investigated.”124

“An obvious limitation of this study is the small sample size; however, despite the
small number of patients, a statistically significant difference was still observed in the
urinary levels of the novel proximal tubule proteins between UPJO patients versus
controls. This study is also limited by lack of matching for age and gender in the two
cohorts; however, since there was no significant difference in these parameters
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between the control and UPJO cohorts, it is unlikely that age or gender had a
significant impact on the observed differences in urinary protein levels. Additionally,
it would be useful to study urinary levels of these proximal tubule proteins after
surgical repair. In this preliminary study, we did not exclude UPJO patients with
other urologic comorbidities that may have potential impact on urinary protein levels.
However, none of the patients had evidence of coexisting obstructive processes,
and the contralateral partial UPJO obstruction in one patient had resolved
spontaneously prior to the ipsilateral pyeloplasty. The two patients with a history of
vesicoureteral reflux had no evidence of reflux nephropathy.”124

“Despite these limitations, our results support the notion that these proximal tubule
proteins may represent more predictive biomarkers of urinary tract obstruction, and
that further study is warranted in patients with UPJO and potentially in other
etiologies of renal injury. We continue to enroll patients with UPJO at our institution
in order to increase our sample size and will begin collecting postoperative urine to
measure renal recovery and assess the viability of our biomarkers. We are also
enrolling control patients that are matched by age and gender to the UPJO patients.
In addition, we are investigating the correlation of these urinary proteins with renal
damage in a murine model of obstruction to further study their potential utility as
biomarkers of renal injury.”124
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4.6 – Conclusions
“Targeted identification of reliable, noninvasive biomarkers of renal injury is critical to
aid in diagnosing patients at risk, guiding therapeutic decisions and monitoring
treatment efficacy. In our study, bladder urinary levels of the proximal tubule brush
border proteins CD10, CD13 and CD26 were significantly higher in patients with
UPJO compared to normal controls, while the levels of KIM-1 and NGAL were not
significantly different between UPJO patients versus controls. These preliminary
results suggest that these novel proximal tubule proteins may prove to be useful
noninvasive biomarkers that are more predictive of urinary tract obstruction. Further
studies are necessary to validate these findings and to determine the correlation of
these urinary protein levels with renal damage.”124
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4.7 – Figures and Legends
FIGURE 4.1 – MODEL OF UUO.
FIGURE 4.2 – CD13 EXPRESSION DECREASES AS UUO PROGRESSES.
FIGURE 4.3 – CD13 PROTEIN IN URINE AND KIDNEY FOLLOWING UUO.
TABLE 4.1 – UPJO PATIENT DEMOGRAPHIC CHARACTERISTICS
TABLE 4.2 – URINARY BIOMARKER VALUES FOR CONTROL AND UPJO SAMPLES
FIGURE 4.4 – URINARY BIOMARKER LEVELS OF KNOWN BIOMARKERS.
FIGURE 4.5 – URINARY BIOMARKER LEVELS OF NOVEL PROXIMAL TUBULE BIOMARKERS.
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Figure 4.1 – Model of UUO.
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Figure 4.2 – CD13 expression decreases as UUO progresses.
(A) Hematoxylin and eosin stain of obstructed murine kidneys at UUO at 1, 3, 5, 7,
and 10 days post ligation show increased tubular damage where proximal tubules
lose their shape and become distended as disease progresses. (B) CD13 (green,
blue=nuclei) expression in the brush border of the proximal tubules over time, 10x
and (C) 40x magnification.
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Figure 4.3 – CD13 protein in urine and kidney following UUO.
Digital quantification of western blot of murine urine samples detects CD13 protein at
early time points. (A) Normalized urinary CD13 levels (ligated/unligated (L/UL))
increases in obstructed kidneys over time. (B) CD13 levels decreased in ligated (L)
as compared to unligated (UL) kidney.
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Table 4.1 – UPJO patient demographic characteristics
Case
#

Gender

Age at
surgery
(months)

Presentation

Laterality

MAG3 Data

Other Urologic
Comorbidities

Surgical
Approac
h

1

Female

32

UTI

Right

t1/2,
minute
s
29

2

Male

4

Prenatal
hydronephrosis

Right

*

19.3

None

Open

3

Female

5

Prenatal
hydronephrosis

Left

43

25.4

Mild right
hydronephrosi
s

Open

4

Male

4

Prenatal
hydronephrosis

Left

329.5

25

None

Open

5

Male

5

Prenatal
hydronephrosis

Left

47

52

None

Robotic

6

Female

22

Prenatal
hydronephrosis

Right

17

34

None

Robotic

7

Male

32

Prenatal
hydronephrosis

Left

*

43

Right partial
UPJO,
resolved
spontaneously

Robotic

8

Male

54

Abdominal pain
and vomiting

Left

*

52

Right grade 4
VUR, treated
with robotic
reimplantation

Robotic

9

Male

76

Postnatal
hydronephrosis

Right

22.5

40

Right VUR,
resolved
spontaneously

Robotic

10

Female

100

UTI

Right

42

39

None

Robotic

11

Male

215

Abdominal pain

Left

*

20

Recurrent
UPJO in
pelvic kidney
after
pyeloplasty
during infancy

Robotic

12

Male

243

Gross hematuria
after renal trauma

Left

45

23

Nephrolithiasi
s

Robotic

•

Unable to calculate due to complete absence of excretion
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Ipsilateral
function, %
N/A

Solitary right
kidney

Robotic

Table 4.2 – Urinary biomarker values for control and UPJO samples
Case
#

Control/
UPJO

Creatinine
(mg/dL)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

UPJO
UPJO
UPJO
UPJO
UPJO
UPJO
UPJO
UPJO
UPJO
UPJO
UPJO
UPJO
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control

29
20
40
7
33
31
42
84
51
110
57
40
72
54
79
103
128
99
278
128
73
71
31
110

CD10/
Creatinine
(RU)
5.77
20.59
9.89
29.05
14.05
5.93
3.46
3.22
2.62
3.19
3.14
6.39
2.62
2.40
2.04
1.51
3.83
1.36
1.28
1.86
2.74
1.45
10.57
4.15

CD13/
Creatinine
(RU)
3.01
30.50
31.14
10.01
45.51
2.19
1.64
2.42
1.13
1.71
0.25
0.62
1.87
1.16
1.09
0.81
2.25
1.19
0.48
0.85
1.30
0.24
1.36
1.19
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CD26/
Creatinine
(RU)
181.13
8188.84
1398.27
290.33
759.16
224.47
113.17
125.94
154.19
198.40
26.84
82.04
116.94
93.87
67.93
63.03
151.36
130.33
33.44
52.86
91.58
48.32
82.00
155.08

KIM-1/
Creatinine
(RU)
5.47
2.30
10.50
0.84
8.92
6.10
7.53
3.12
3.62
3.90
0.16
3.54
10.15
4.93
1.22
13.37
12.75
5.01
1.07
4.76
1.47
0.46
2.79
8.98

NGAL/
Creatinine
(RU)
28.89
76.59
9587.33
628.83
67.69
32.30
11.93
6.15
263.00
0.24
10.63
118.56
55.82
19.01
29.75
27.71
191.19
14.33
77.73
16.01
100.14
154.43
37.21
74.87

B

KIM-1

NGAL

NGAL/Creatinine

KIM-1/Creatinine

A

Control

UPJO

Control

UPJO

Figure 4.4 – Urinary biomarker levels of known biomarkers.
Box plot of urinary levels of KIM-1 (A) and NGAL (B) normalized to creatinine in
control and UPJO patients. Data expressed in relative units.
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Figure 4.5 – Urinary biomarker levels of novel proximal tubule biomarkers.
Box plot of urinary levels of CD10 (A), CD13 (B) and CD26 (C) normalized to
creatinine in control and UPJO patients. Data expressed in relative units. * p < 0.05;
** p < 0.01
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Chapter 5
Concluding Remarks

________________________________
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5.1 – Summary of findings and future directions
CD13 has been identified to regulate various physiological functions including
angiogenesis, inflammation and endocytosis70. However, the exact mechanisms in
which CD13 functions remains unclear. Since CD13 is highly expressed on
monocytes and activated endothelial as well as renal proximal tubule cells, this study
utilized various models to identify how CD13 regulates inflammation and endocytosis.
This thesis focused on (1) identifying domain specific functions of CD13 in regards to
inflammation, (2) how CD13 mediated endocytic uptake in response to renal injury
and (3) the possibility of CD13 as an early predictor of renal injury in patients with
UPJO.

The first investigation of this thesis focused on an in depth evaluation on the
structure and functional analysis of CD13 in regards to inflammation. Prior to starting
the project, it was known that mice lacking CD13 had altered trafficking of
inflammatory cells to the site of injury after hindlimb ischemia and myocardial
infarction86,97. It was hypothesized that the extracellular domain of CD13 would
regulate important homotypic adhesion functions between the activated epithelial
layer of injured tissues and circulating monocytes. First, pro-inflammatory subsets of
monocytes were higher in WT mice compared to CD13KO mice indicating that CD13
may regulate trafficking of immune cells to the site of injury. In a model of
thioglycollate peritonitis peritoneal monocytes, macrophages and DCs were
diminished in CD13KO mice. Further, the study used chimeras to identify that
homotypic adhesion of CD13 is species specific by using in vitro adhesion assays as
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well as in vivo thioglycollate-induced peritonitis. Blocking CD13 mimicked the results
observed in CD13 deficient mice indicating that pro-inflammatory processes can be
manipulated with treatment. Finally, it was determined that the C-terminal domain is
the specific site for homotypic adhesion. This work established that CD13 regulates
inflammatory response by mediating myeloid cell subset trafficking. The in vitro
analysis indicates that this phenomenon will translate into humans, but finding a
blocking agent specific for monocytes remains challenging. Finally, utilizing CD13KO
mice can give insight into pro-inflammatory versus anti-inflammatory immune
reactions and identifying which inflammatory response aids specific recovery
mechanisms beyond peritonitis, hindlimb ischemia and coronary occlusion.

Diabetes mellitus is an intricate disease affecting multiple organs including the
pancreas and kidney. ESRD is a common cause of death in patients experiencing
diabetic nephropathy. Multiple models of renal injury were utilized to identify the
contribution of CD13 to the progression of disease pathology in diabetic nephropathy
and to determine the role of CD13 in plasma protein uptake by the proximal tubules.
Healthy, renal proximal tubule epithelial cells are equipped with endocytic machinery
to efficiently reabsorb glomerular filtrates. However, some diabetics develop
nephropathy prompted by hyperglycemia which is the driving component that leads
to glomerular damage, gradual nephron deterioration, overload of proximal tubule
reabsorption mechanisms and leakage of protein into the urine. Albuminuria is a
strong indicator of renal injury, but albuminuria itself may contribute to renal disease
progression. CD13KO mice had significantly reduced albuminuria in a model of
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diabetic nephropathy as well as AO. CD13 deficient renal proximal tubules were able
to take up albumin more efficiently compared to WT proximal tubules. CD13 did not
co-localize with the megalin receptor in renal tubules. Interestingly, it did co-localize
with the FcRn receptor, which is responsible for the transcytosis of albumin back into
the circulation. This study further identified the effects of albuminuria on renal injury.
Increased albumin uptake did not lead to more necrosis or apoptosis of renal cells
when analyzed by flow analysis. These investigations provide new insight into
albuminuria and how it leads to renal injury. It appears to be a combination of
increased renal uptake in addition to excess fragmented albumin in the nephron that
causes sublethal damage leading to ESRD. Future studies still need to address the
precise mechanism in which albuminuria contributes to renal injury by utilizing more
models of renal failure. Longer time points after diabetic onset could identify if
decreased albuminuria leads to slower progression of renal injury. Further
investigations can provide more insight into clinical targets that can reduce nephron
loss at earlier time points as clinical interventions today just focus on slowing
disease progression.

Congenital anomalies like UPJO often lead to renal injury. Increased intrarenal
pressure due to obstruction initiates an injury-signaling cascade resulting in renal
dysfunction. Despite growing insight into disease progression, early diagnostic
markers that reliably detect renal obstruction are severely lacking. Current diagnostic
tests primarily rely on serum creatinine, which remains unchanged until half the
nephron volume is lost. Alternative tests include invasive nuclear scans, which also
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requires waiting until significant renal functional loss occurs. The third study of this
thesis aimed to identify reliable biomarkers that have the potential to diagnose
patients at risk, guide therapeutic options and monitor treatment to improve patient
care and reduce associated morbidities. It was hypothesized that single-pass,
apically expressed proximal tubule brush border proteins including CD13, CD10 and
CD26 would shed into the urine early and act as reliable non-invasive urinary
biomarkers. A murine model of UUO was initially used to experimentally determine
whether renal injury correlated with urinary CD13 levels. CD13 expression
decreased in obstructed kidneys and increased in urine. A prospective cohort study
was performed at Connecticut Children’s Medical Center. Bladder urine samples
were collected and analyzed for proximal tubule markers as well as previously
published biomarkers, NGAL and KIM1. Proximal tubule brush border proteins are
reliably detected in the urine of UPJO patients and outperformed previously
established biomarkers in a small sample of patients. This preliminary study
identifies new, non-invasive biomarkers that outperform previously published
biomarkers. Results from this investigation determined that these biomarkers are
elevated in UPJO patients, but it has still to be determined if these biomarkers are
capable of distinguishing between UPJO patients and those with suspected
hydronephrosis. Patients with suspected hydronephrosis do not require surgical
intervention, thus it is imperative that these biomarkers accurately detect obstructive
damage. Further investigations need to determine if these biomarkers can eliminate
current clinical evaluation tools by correlating biomarker levels with total renal
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damage by histological stratification. Perhaps this panel of biomarkers can be
utilized to assess other forms of renal injury as well.

5.2 – Clinical Implications
The multifunctional nature of CD13 suggests that CD13 has clinical implications in
various settings including in inflammatory responses after injury. The human
immune system is highly complex and regulated by various cells and signaling
components146. Monocytes are recruited to mitigate the effects of viral, bacterial or
fungal infections and tissue injuries. These monocytes might contribute to the
pathogenesis of inflammatory and degenerative disease. To avoid more injury, the
immune system must maintain homeostasis of various pro- and anti-inflammatory
signaling147. Pro-inflammatory cytokines are released to resolve injury, while antiinflammatory cytokine inhibitors limit the possibly harmful consequences of
sustained or excessive levels of inflammatory reactions146. CD13KO mice have
abnormal trafficking of monocytes to the site of injury and infection. Abnormal
trafficking in response to inflammation can lead to skewed immune responses that
lead to improper healing at the site of injury. Recruitment of the appropriate
monocytes by the innate immune system to the site of injury is vital for resolution of
injury.

While albuminuria is a strong indicator of renal injury, albuminuria may be causal to
disease progression. Thus reducing albumin in the urine is a viable therapeutic goal
for diabetic patients148. A new endocytic regulator that controls physiological
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processes in the kidney was discovered. CD13 deficient mice had significantly less
albuminuria 20 weeks after the onset of diabetes compared to WT mice. Blocking
CD13 in renal proximal tubules could allow for increased uptake of albumin by
proximal tubules, which might offer some protection to the nephron in the
progression of renal deterioration. New therapies that involve increased albumin
uptake in the proximal tubule might halt the progression of ESRD and premature
death caused by diabetic nephropathy.

Mechanisms to assess the severity of damage caused by UPJO are decisively
lacking and primarily rely on insensitive tests from serum creatinine which remains
unchanged until greater than 50% nephron volume is lost. Alternatively, differential
renal function is determined by invasive nuclear scans, which requires waiting until
significant functional loss occurs17. Current treatment for UPJO consists of surgical
reconstruction in obvious cases or a watchful waiting approach in asymptomatic
patients who have not yet demonstrated loss of differential function on renal nuclear
scan, which may be deleterious to young infants where significant renal
development occurs both pre- and post-natally. The inability to assess evolving renal
damage leaves the physician to base critical decision on inadequate information.
Therefore, the discovery and identification of new reliable biomarkers has the
potential to diagnose patients at risk, guide therapeutic options and potentially
monitor treatment, significantly improving patient care and reducing morbidity. The
initial identification of reliable biomarkers might be a useful tool guiding physicians in
their treatment strategies.
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